

# CURRICULUM VITAE

**Jennifer Robinson Diamond, M.D.**  
**August 2025**

---

**PERSONAL DATA****Jennifer Robinson Diamond, M.D.**

Professor of Medicine with Tenure  
University of Colorado of Medicine (UCSOM)  
Department of Medicine  
Division of Medical Oncology  
Developmental Therapeutics and Breast Oncology Programs  
Mail Stop 8117, 12801 E. 17<sup>th</sup> Avenue, Room 8112  
Aurora, CO 80045  
E-mail: [Jennifer.Diamond@cuanschutz.edu](mailto:Jennifer.Diamond@cuanschutz.edu)

**EDUCATION**

1995-2000	Bachelor of Arts, Magna Cum Laude Biochemistry University of Arizona Tucson, AZ
2000-2004	Doctor of Medicine University of Arizona College of Medicine Tucson, AZ
2004-2007	Internship and Residency, Internal Medicine University of Colorado Health Sciences Center Robert Anderson, M.D., Chair Denver, CO
2007-2010	Fellowship, Medical Oncology University of Colorado Health Sciences Center S. Gail Eckhardt, M.D., Chair Denver, CO

**ACADEMIC APPOINTMENTS**

2025-Present	Professor with Tenure, Department of Medicine Division of Medical Oncology University of Colorado School of Medicine
2023-Present	Special Faculty Appointment, Biomedical Sciences and Biotechnology (BSBT) program University of Colorado Graduate School
2017-2025	Associate Professor, Department of Medicine Division of Medical Oncology University of Colorado School of Medicine
2014-2016	Special Faculty Appointment, Cancer Biology, Graduate School University of Colorado Anschutz Medical Campus

2010-2017 Assistant Professor, Department of Medicine  
Division of Medical Oncology  
University of Colorado School of Medicine

#### **INSTITUTIONAL POSITIONS**

2024-Present Medical Director, Cancer Clinical Trials Office  
University of Colorado Cancer Center

2021-Present Program Director, Developmental Therapeutics Fellowship training program  
University of Colorado School of Medicine

2020-Present Clinical Research Director, Phase I, Expansion and Molecular  
Studies (POEMs) Program  
University of Colorado Cancer Center

2019-Present Joyce M. Brown Chair for Developmental Therapeutics in Women's Cancers  
University of Colorado Cancer Center

2016-2019 Medical Director, Cancer Clinical Trials Office  
University of Colorado Cancer Center

2016-Present Founding Co-Director, Women's Cancer Developmental Therapeutics Program  
University of Colorado Cancer Center

2012-2016 Director, Data and Safety Monitoring Committee  
University of Colorado Cancer Center

2012-Present Full Member, Developmental Therapeutics Program  
University of Colorado Cancer Center

2010-2011 Associate Member, Developmental Therapeutics Program  
University of Colorado Cancer Center

2010-Present Staff Physician, University of Colorado Hospital  
Anschutz Medical Campus, Aurora, CO

#### **INDUSTRY POSITIONS**

2023-Present Consultant and Advisory Board Member, OnKure Therapeutics, Boulder, CO

2021-2023 Chief Medical Officer (CMO), OnKure Therapeutics, Boulder, CO

- Fractional CMO for biotech company focused on the development of anti-cancer agents targeting oncogenes.
- Responsible for oversight of clinical operations for clinical assets, including protocol development and clinical aspects of IND submission for international Phase I first-in-human study and Phase II clinical trial.
- Managing clinical operations for life cycle of the protocol, including contributing to preclinical data generation, protocol development, site

selection, investigator communications and data analysis.

#### **CLINICAL ACTIVITIES**

2010-Present      Medical Oncology attending (1.5 days per week)

Providing care in the outpatient Breast Cancer clinic at the University of Colorado Hospital (UCH). Caring for patients with breast cancer receiving standard of care therapy or being treated in research trials. Supervising medical students, interns, residents, medical oncology fellows in this clinic.

2010-Present      Medical Oncology attending (2 weeks per year)

Providing care in the inpatient Oncology Service and as Oncology consultant hospital-wide at UCH. Supervising Internal Medicine residents and Oncology fellows, consulting on and taking care of up to 30 admitted or emergency department patients per day.

#### **HONORS, SPECIAL RECOGNITIONS AND AWARDS**

- 2019              Joyce M. Brown Inaugural Chair Recipient, Developmental Therapeutics in Women's Cancers  
University of Colorado Cancer Center
- 2016              University of Colorado Anschutz Medical Campus,  
Excellence in Clinical Care Award
- 2013-2017      Clinical Loan Repayment Program (LRP) Award  
Recipient, National Institutes of Health, National Cancer Institute
- 2013-2018      Mentored Patient-Oriented Research Career Development Award (K23)  
Recipient, National Institutes of Health, National Cancer Institute  
The development of novel individualized therapy for triple-negative breast cancer
- 2012-2013      Paul Calabresi Career Development Award for Clinical Oncology (K12)  
Recipient, National Institutes of Health, National Cancer Institute.  
New drug development for the treatment of triple-negative breast cancer  
with novel patient selection strategies
- 2011              Selected Participant  
Cancer Education Consortium Workshop  
Molecular and Translational Oncology, Santa Cruz, CA
- 2008-2010      NIH T32 Training Grant Recipient  
Medical Oncology Fellow, University of Colorado
- 2009              Selected Participant  
Cancer Education Consortium Workshop  
Clinical Pharmacology of Anticancer agents, Washington D.C.
- 2009              Selected Participant  
ASCO/AACR Workshop

- Methods in Clinical Cancer Research, Vail, CO
- 2008 Fellow Travel Award recipient  
10<sup>th</sup> Annual Lynn Sage Breast Cancer Symposium  
Medical Oncology Fellow, University of Colorado
- 2004 Alpha Omega Alpha, Honor Medical Society, Elected member  
University of Arizona College of Medicine
- 2004 Excellence in Research Award, University of Arizona College of Medicine  
Circulating endothelial cells as a surrogate of response to therapy  
in metastatic breast cancer
- 2004 Glasgow-Rubin Achievement Citation  
American Medical Women's Association  
University of Arizona College of Medicine
- 2000-2004 Jeremiah Metzger Scholarship Recipient  
University of Arizona College of Medicine
- 2000-2004 Robert F. Allen Memorial Scholarship Recipient  
University of Arizona College of Medicine
- 2000 BRAVO International Scholar, University of Tübingen, Germany  
Glucose and lipid metabolism in the skeletal muscle of patients  
with HIV on antiretroviral therapy
- 1999 Phi Eta Sigma Honor Society Induction, University of Arizona
- 1998 Phi Beta Kappa Honor Society Induction, University of Arizona
- 1998 Golden Key National Honor Society Induction, University of Arizona
- 1998 International Scholar, Biophysical Chemistry  
University of Uppsala, Sweden

**MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS**

- 2009-Present Active Member, American Association of Cancer Research (AACR)
- 2009-Present Member, American Society of Clinical Oncology (ASCO)
- 2009-Present Member, Women in Cancer Research, AACR

**MAJOR COMMITTEES AND SERVICE RESPONSIBILITIES****National Committees**

- 2023-Present Data Strategy Workgroup  
Oncology Research Information Exchange Network (ORIEN)  
Role: Member
- 2023-Present Breast Cancer Committee

- Alliance  
Role: Member
- 2023-Present Phase I Disease-Focused Investigator Group  
Experimental therapeutics clinical trials network (ETCTN)  
Role: Member
- 2022 San Antonio Breast Cancer Update, National Virtual Meeting  
Role: Planning Committee and Faculty
- 2021 AACR Annual Scientific Meeting Program Committee  
Mechanisms of Drug Action Section, Experimental and Molecular Therapeutics  
Subcommittee  
Role: Member
- 2021-2024 ORIEN Annual Symposium, Scientific Program Committee  
Role: Member
- 2021-Present ASCO Self-Evaluation Program (SEP) Item Writing Task Force  
Role: Member
- 2021-Present Breast Disease-Focused Investigator Group  
ETCTN  
Role: Member
- 2020-Present ORIEN Clinical Trial Network  
Clinical Trials Committee  
Role: Chair
- 2019 AACR Annual Scientific Meeting Program Committee  
Mechanisms of Drug Action Section, Experimental and Molecular Therapeutics  
Subcommittee  
Role: Chair
- 2016-Present Breast Cancer Committee  
Southwest Oncology Group (SWOG)  
Role: Member
- 2016-Present Early Therapeutics & Rare Cancers Committee  
SWOG  
Role: Member
- 2016-2020 ORIEN Phase I Working Group  
Role: Member

**Local Committees**

- 2021-Present Hispanic Cancer Outreach Steering Committee  
University of Colorado Cancer Center  
Role: Member
- 2021 San Antonio Breast Cancer Update, Denver, CO

	Role: Planning Committee and Faculty
2020	San Antonio Breast Cancer Update, Denver, CO Role: Planning Committee and Faculty
2016-2022	Cancer Clinical Trials Office Financial Advisory Committee, Aurora, CO Role: Member
2015-2019	Investigator-Initiated Trials Feasibility Committee University of Colorado Cancer Center Role: Member
2015	Service Committee Division of Medical Oncology, University of Colorado Role: Co-Chair
2014	Mountain States Cancer Conference (CME), Aurora, CO Role: Planning Committee and Conference Chair
2012-2019	Clinical Research Leadership Committee University of Colorado Cancer Center Role: Member
2012-2014	Colorado Multiple Institutional Review Board (COMIRB) University of Colorado Anschutz Medical Campus Role: Physician Reviewer, Standing Panel Member
2011-Present	Cancer Research Summer Fellowship Program University of Colorado Cancer Center Role: Mentor, Faculty and Speaker
2011-2012	Epic Beacon Go-Live Committee, University of Colorado Hospital Role: Breast Cancer Physician Team Lead
2011-2012	Protocol Quality Adherence Safety Committee University of Colorado Cancer Center Role: Member
2009-Present	Medical Oncology Fellowship Selection Committee University of Colorado Anschutz Medical Campus Role: Member
2008-2009	Housestaff Association Executive Committee Graduate Medical Education University of Colorado Health Sciences Center Role: Member
2008-2009	Board of Directors Graduate Medical Education Health Benefits University of Colorado Health Sciences Center

Role: Member

2008-2012 Internal Medicine Residency Selection Committee  
University of Colorado Health Sciences Center  
Role: Member

2006-2007 Curriculum Committee  
Internal Medicine Residency Program  
University of Colorado Health Sciences Center  
Role: Member

### **Community Service**

2024 V Foundation, Patient Education Series, Demystifying Clinical Research  
Miami Cancer Institute

2016 Learn About Cancer Day, Faculty and Facilitator  
Educational Outreach Program for local High School students  
University of Colorado Anschutz Medical Campus

2016 Keynote presentation to patients, supporters and the community at a Symposium  
sponsored by the Gynecologic Oncology Council – “Harnessing the immune  
system to fight gynecologic cancers”

2015-2021 Grant Review Panel  
Susan G. Komen Colorado  
Role: Scientific Reviewer

2015 Learn About Cancer Day, Faculty and Facilitator  
Educational Outreach Program for local High School students  
University of Colorado Anschutz Medical Campus

2012 Presentation at Anschutz Cancer Foundation charity golf tournament – “Clinical  
trials for Breast Cancer”, Colorado Springs, CO

2012 Anschutz Medical Campus Cancer Fund, Faculty and Speaker  
Educational Outreach Program for cancer patients  
University of Colorado Anschutz Medical Campus

2011 Presentation to cancer patients – “Clinical trials for cancer patients”  
Colorado Cancer Day, Faculty and Speaker  
University of Colorado Anschutz Medical Campus

2010 Presentation to local high school students – “Phase I clinical trials and cancer”  
Learn About Cancer Day, Faculty and Speaker  
University of Colorado Anschutz Medical Campus

2009 Presentation to local high school students – “Phase I clinical trials and cancer”  
Learn About Cancer Day, Faculty and Speaker  
University of Colorado Anschutz Medical Campus



2009 Presentation to cancer patients – “Cancer clinical trials – Guinea pigs or test pilots”  
 Colorado Cancer Day, Faculty and Speaker  
 Educational Outreach Program for cancer patients  
 University of Colorado Anschutz Medical Campus

#### **LICENSURE AND BOARD CERTIFICATIONS**

2007-Present	Colorado, State Medical License
2007-2017, 2021-Present	American Board of Internal Medicine (ABIM), Diplomate, Internal Medicine
2010-Present	ABIM Diplomate, Medical Oncology

#### **EDITORIAL REVIEW AND REFEREE WORK**

##### **National Grant Review Committees and Study Sections**

2024	National Institutes of Health (NIH)/National Cancer Institute (NCI), Specialized Programs of Research Excellence (SPOREs) Role: Scientific Reviewer
2023	Congressionally Directed Medical Research Programs (CDMRP) Breast Cancer Research Program (BCRP) Role: Chair
2022	NIH/ NCI, SPORE Study Section Role: Scientific Reviewer
2022	CDMRP BCRP Role: Chair
2021	CDMRP BCRP Role: Chair
2020	NIH/ NCI, R21/R03 Clinical and Translational Exploratory/Developmental Studies Role: Scientific Reviewer
2020	CDMRP BCRP Role: Chair
2019	NIH/ NCI, R21/R03 Clinical and Translational Exploratory/Developmental Studies Role: Scientific Reviewer
2019	CDMRP BCRP Role: Scientific Reviewer
2018	CDMRP BCRP Role: Scientific Reviewer
2018	National Institutes of Health (NIH)/National Cancer Institute (NCI), R21/R03 Clinical and Translational Exploratory/Developmental Studies Role: Scientific Reviewer

2016 CDMRP BCRP Scientific Reviewer  
Role: Scientific Reviewer

2015 CDMRP BCRP Scientific Reviewer  
Role: Scientific Reviewer

2014 CDMRP BCRP Scientific Reviewer  
Role: Scientific Reviewer

2013 CDMRP BCRP  
Role: Scientific Reviewer

### **Local Grant Review Committees**

2019-2025 Boettcher Foundation Webb-Waring Biomedical Research Awards  
Role: Scientific Reviewer

2018-2024 American Cancer Society Grant Review Committee  
Role: Scientific Reviewer

2015-2021 Susan G. Komen Colorado Grant Review Panel  
Role: Scientific Reviewer

2011-2013 Cancer League of Colorado Grant Program  
Role: Scientific Reviewer

### **Scientific Advisory Positions**

2023-Present Scientific Advisory Board, OnKure Therapeutics, Boulder, CO

2023 Scientific Advisor Board, Daiichi Sankyo

2022-Present Gilead Hope Oncology Partnership

2011-2013 Scientific Advisor Board, Cancer League of Colorado

2017 Scientific Advisor Board, Boehringer Ingelheim Early Pipeline Oncology

2019 – 2022 Scientific Advisor Board, Gilead Breast Cancer Council

### **Editorial Activities**

2022-2025 Cancers  
Role: Special Issue Editor Targeted therapies in Cancer

2021-present Frontiers in Oncology and Frontiers in Cell and Developmental Biology  
Review Editor, Molecular and Cellular Oncology

2020-present Cancers, Editorial Board

2010-present Ad hoc reviewer: *Journal of Clinical Oncology, Clinical Cancer Research, British Journal of Cancer, Molecular Cancer Therapeutics, Nature Nanotechnology, Breast Cancer Research, Breast Cancer Research and Treatment, Journal of Immunotherapy of Cancer, Onkologie, Critical Reviews in Oncology/Hematology, Oncotarget, Pharmacology and Therapeutics*

#### INVITED EXTRAMURAL LECTURES, PRESENTATIONS, AND VISITING PROFESSORSHIPS

##### Invited Lectures: National/International Meetings

1. Clinical Trials 101: V Foundation Series, Miami Cancer Institute, Miami, FL, 2024.
2. Metastatic Breast Cancer Update. Best of ASCO National Meeting, Scottsdale, Arizona, 2023.
3. Trial Matching for Patients with Cancer: ORIEN Clinical Trials Network. ORIEN Annual Scientific Meeting, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, 2023.
4. Improving Breast Cancer Outcomes by Managing Long-Term Side Effects. Mountain States Cancer Conference, University of Colorado Cancer Center, Aurora, CO, 2023.
5. Triple-Negative Breast Cancer – Early Stage Disease. ESMO and SABCS update. Virtual National Horizon CME Meeting (due to COVID-19 pandemic), 2022.
6. ORIEN Clinical Trials Network – Leveraging Partnerships. ORIEN Annual Scientific Retreat, Tampa, Florida, 2022.
7. Triple-Negative Breast Cancer. Updates from SABCS and ESMO. Horizon CME Conference, Virtual National meeting (due to COVID-19 pandemic), 2021.
8. Clinical Expert-led ESMO 2021 Highlights. Gilead International Educational Webinar (due to COVID-19 pandemic), 2021.
9. Optimizing the Paradigm Shift Driven by CDK 4/6 Inhibition in Metastatic HR-Positive, HER2-Negative Breast Cancer. Grand Rounds Prescott VA Hospital, Prescott, AZ, Virtual presentation (due to COVID-19 pandemic), 2020.
10. Triple-Negative Breast Cancer. Advances in Breast Cancer: Updates from SABCS and ESMO. Horizon CME Conference, Denver, CO, 2020.
11. Immunotherapy for Breast Cancer: Updates from SABCS and ESMO. Horizon CME Conference, Denver, CO, 2020.
12. Moving Towards Targeted Therapies for Triple-Negative Breast Cancer. Grand Rounds, University of Texas Southwestern, Dallas, TX, 2019.
13. Integrating CDK 4/6 Inhibitors in the Treatment of Metastatic Breast Cancer. Mountain States Cancer Conference, University of Colorado Cancer Center, Aurora, CO 2018.

14. The Multidisciplinary Team Approach: Optimizing Breast Cancer Therapy in the Targeted Treatment Era. Tumor Board Grand Rounds Series. Saginaw VA Hospital, Saginaw, MI, 2018.
15. A 3-D View of Novel Targeted Agents in Metastatic, Hormone Receptor Positive, HER-2 Negative Breast Cancer. Saint Anthony Hospital, Chicago, IL, 2018.
16. A 3-D View of Novel Targeted Agents in Metastatic, Hormone Receptor Positive, HER-2 Negative Breast Cancer. Washington Medstar Washington Cancer Institute, Washington, DC, 2018.
17. Immunotherapy for Cervical Cancer, American Radium Society, 99<sup>th</sup> Annual Meeting, Colorado Springs, CO, 2017.
18. Triple-Negative Breast Cancer. Society of Utah Medical Oncologists, Fall Meeting, Park City, UT, 2015.
19. Triple-Negative Breast Cancer. Mountain States Cancer Conference, Aurora, CO 2013.
20. Saving Lives with Cancer Screening and Chemoprevention, 48<sup>th</sup> Annual Internal Medicine Review Program, Estes Park, CO, 2012.
21. Triple-negative Breast Cancer. 2<sup>nd</sup> Annual Western Slope Oncology Conference, Montrose, CO, 2012.

**Invited Lectures: Local/Regional**

1. Update on Clinical Research Methods: Response Evaluation Criteria in Solid Tumors. Cancer Clinical Trials Office, University of Colorado Cancer Center, Aurora, CO, 2024.
2. ASCO Update: New Implications for Capecitabine. University of Colorado Health System Wide Breast Cancer Symposium, Aurora, CO, 2023.
3. University of Colorado Cancer Center Clinical Trial Operations. Gilead-UCCC Research Summit, Aurora, CO, 2023.
4. Triple-Negative Breast Cancer: Updates on Treatment of Early- and Late-Stage Disease. MLS Oncology Conference, Denver, CO, 2023.
5. RECIST for Clinical Trials Update. University of Colorado Cancer Center Clinical Trials Office, Aurora, 2022.
6. Phase I Trial of OKI-179, an Oral Class-I-Targeting Depsipeptide HDAC Inhibitor, in Patients with Advanced Solid Tumors. Oncology Clinical Research (OCRST) Lecture Series, University of Colorado Cancer Center, Aurora, CO, 2022.
7. Breast Cancer. OncLive State of the Science Summit, Denver, CO 2022.
8. Overcoming Treatment-induced Senescence as a Mechanism of Resistance to Anti-Cancer Therapies. University of Colorado School of Medicine, Innovation Seminar, Aurora, 2021.

9. Breast Cancer. University of Colorado Cancer Center Lunch and Learn, Aurora, CO, 2021.
10. Triple-Negative Breast Cancer. University of Colorado Health System Wide Breast Cancer Symposium, Virtual Meeting (due to COVID-19 pandemic), 2020.
11. Drug Development in Triple-Negative Breast Cancer. University of Colorado Health System Wide Breast Cancer Symposium, Fort Collins, CO, 2019.
12. Moving Towards Targeted Therapies for Triple-Negative Breast Cancer. Kaiser Permanente Colorado, Denver, CO, 2019.
13. Triple-Negative Breast Cancer: Moving Towards Targeted Systemic Therapies. Department of Medicine Grand Rounds, University of Colorado School of Medicine, Aurora, CO, 2018.
14. A 3-D View of Novel Targeted Agents in Metastatic, Hormone Receptor Positive, HER-2 Negative Breast Cancer. Grand Junction, CO, 2018.
15. Rational Combination of Torc1/2 and Aurora Kinase Inhibitors in Triple Negative Breast Cancer. ORIEN Phase I Working Group Presentation, 2018.
16. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. University of Colorado Health, System Wide Breast Lecture, Aurora, CO, 2017.
17. New Targeted Therapies for Triple-Negative Breast Cancer: From Bench to Bedside and Back Again, University of Colorado Health, System Wide Breast Cancer Annual Retreat, Aurora, CO, 2017.
18. Harnessing the Immune System to Fight Gynecologic Cancers. Gynecologic Oncology Symposium, University of Colorado Cancer Center, Aurora, CO, 2016.
19. Novel Targeted Phosphorylated p68 Inhibitor RX-5902 Shows Activity in Triple-Negative Breast Cancer. Developmental Therapeutics Program Retreat, University of Colorado Cancer Center, Aurora, CO, 2016.
20. Mechanisms of Resistance to Aurora Kinase Inhibitors in TNBC. University of Colorado Cancer Center, Symposium Series, Aurora, CO, 2016.
21. Rational Combination of Torc1/2 and Aurora Kinase Inhibitors in Triple-Negative Breast Cancer. Developmental Therapeutics Education Conference, University of Colorado Cancer Center, Aurora, CO, 2015.
22. Mediators of Terminal Cellular Fate in Response to Aurora kinase Inhibitors in Triple-Negative Breast Cancer. Hormone Related Malignancies Retreat, University of Colorado Cancer Center, Aurora, CO, 2014.
23. p53 as a Modulator of Response to Aurora Kinase Inhibition in Triple Negative Breast Cancer. Research and Innovation Conference, University of Colorado School of Medicine, Aurora, CO, 2014.

24. Cell Cycle Inhibitors in TNBC. Paul Calabresi Scholar Lecture Series, University of Colorado Cancer Center, Aurora, CO, 2013.
25. Triple Negative Breast Cancer. Metro Denver Oncology Nursing Society, Denver, CO, 2013.
26. Aurora and Angiogenic Kinase Inhibition in Triple-Negative Breast Cancer. Research in Progress Seminar Series, University of Colorado School of Medicine, Division of Medical Oncology, Aurora, CO, 2012.
27. Triple Negative Breast Cancer. Metro Denver Oncology Nursing Society, Denver, CO, 2012.
28. Advances in the Development of Targeted Therapies for Triple-Negative Breast Cancer. University of Colorado School of Medicine, Department of Medicine Grand Rounds, Aurora, CO, 2012.
29. The Development of Targeted Therapies for Triple-Negative Breast Cancer. Symposium Series, University of Colorado Cancer Center, Aurora, CO, 2012.
30. The Role of p53 in Mediating Sensitivity to Aurora Kinase Inhibitors in Triple-Negative Breast Cancer. Annual Retreat, University of Colorado Cancer Center, Aurora, CO, 2012.
31. Denosumab for the Treatment of Skeletal Metastases in Breast Cancer. Breast Cancer Research Seminar Series, University of Colorado School of Medicine, Aurora, CO, 2011.
32. Aurora and Angiogenic Kinase Inhibition in Triple-Negative Breast Cancer. Research and Innovation Conference, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, 2011.
33. Clinical Trials for Cancer Patients. Colorado Cancer Day, General Patient Session, University of Colorado Cancer Center, Aurora, CO, 2011.
34. Breast Cancer Clinical Trials for Breast Cancer Patients. Colorado Cancer Day, Breast Cancer Session, University of Colorado Cancer Center, Aurora, CO, 2011.
35. Aurora Kinase Inhibitors in Breast Cancer. Hormone Related Malignancies Seminar Series, University of Colorado Cancer Center, Aurora, CO, 2010.
36. Testing New Drugs in Patients: The Phase I trials. Learn About Cancer Day, University of Colorado Cancer Center, Aurora, CO, 2010.
37. Medullary Thyroid Cancer. Fellow's Conference Series, University of Colorado Cancer Center, Aurora, CO, 2010.
38. Clinical Trials: Guinea Pigs, Test Pilots, or Prize Poodles? Mountain States Cancer Conference, University of Colorado Cancer Center, Aurora, CO, 2010.
39. ENMD-2076, a Novel Multi-Targeted Inhibitor of Aurora A and VEGFR2, in Combination with Carboplatin in Patients with Metastatic Triple-Negative Breast Cancer. Breast Cancer Research Seminar Series, University of Colorado School of Medicine, Aurora, CO, 2009.

40. Clinical trials: Guinea pigs, Test Pilots, or Prize Poodles? Colorado Cancer Day, University of Colorado Cancer Center, Aurora, CO, 2009.
41. Aurora Kinase Inhibitors in Breast Cancer. Medical Oncology Recruitment Seminar, University of Colorado Cancer Center, Aurora, CO, 2009.
42. Sorafenib in Advanced Hepatocellular Carcinoma. Medical Oncology Journal Club, University of Colorado Cancer Center, Aurora, CO, 2009.
43. Testing New Drugs in Patients: The Phase I trials, Learn About Cancer Day, University of Colorado Cancer Center, Aurora, CO, 2009.

#### **TEACHING AND MENTORSHIP RECORD**

##### **Presentations to Medical Students, Residents, Fellows**

2024	Cancer Research Summer Fellowship Program Lecture, "Introduction to Breast Cancer: Clinical Management and New Therapies", University of Colorado Cancer Center, Aurora, CO
2023	School of Public Health Lecture, "Introduction to Breast Cancer: Clinical Management and New Therapies", University of Colorado, School of Medicine, Aurora, CO
2023	Cancer Research Summer Fellowship Program Lecture, "Introduction to Breast Cancer: Clinical Management and New Therapies", University of Colorado Cancer Center, Aurora, CO
2023	Oncology Fellows Lecture, "Triple Negative Breast Cancer-Update on Systemic Therapies and Immunotherapy", University of Colorado, School of Medicine, Aurora, CO
2022	Cancer Research Summer Fellowship Program Lecture, "Breast Cancer: The Basics and Advances in Immunotherapy", University of Colorado Cancer Center, Aurora, CO
2022	School of Public Health Lecture, "Introduction to Breast Cancer: Clinical Management and New Therapies", University of Colorado, School of Medicine, Aurora, CO.
2022	Oncology Fellows Lecture, "Triple Negative Breast Cancer-Update on Systemic Therapies and Immunotherapy", University of Colorado, School of Medicine, Aurora, CO
2021	Oncology Fellows Lecture, "Triple Negative Breast Cancer-Update on Systemic Therapies and Immunotherapy", University of Colorado, School of Medicine, Aurora, CO
2021	Cancer Research Summer Fellowship Program Lecture, "Breast Cancer: The Basics and Advances in Immunotherapy", University of Colorado Cancer Center, Aurora, CO

- 2021 School of Public Health Lecture, "Introduction to Breast Cancer: Clinical Management and New Therapies", University of Colorado, School of Medicine, Aurora, CO.
- 2020 Cancer Research Summer Fellowship Program Lecture, "Breast Cancer", University of Colorado Cancer Center, Aurora, CO
- 2020 Oncology Fellows Lecture, "Triple Negative Breast Cancer-Update on Systemic Therapies and Immunotherapy", University of Colorado, School of Medicine, Aurora, CO
- 2019 Cancer Research Summer Fellowship Program Lecture, "Breast Cancer", University of Colorado Cancer Center, Aurora, CO
- 2019 Oncology Fellows Lecture, "Moving Towards Targeted Therapies for Triple Negative Breast Cancer", University of Colorado, School of Medicine, Aurora, CO
- 2018 Cancer Research Summer Fellowship Program Lecture, "Breast Cancer: Clinical Management and New Therapies on the Horizon", University of Colorado Cancer Center, Aurora, CO
- 2018 Oncology Fellows Lecture, "Triple Negative Breast Cancer-Update on Systemic Therapies and Immunotherapy", University of Colorado, School of Medicine, Aurora, CO
- 2018 Integrated Organ Systems 6 PHRD 6750 Pharmacology Student Lecture, "Introduction to Breast Cancer" University of Colorado School of Pharmacy, Aurora, CO
- 2017 Cancer Research Summer Fellowship Program Lecture, "Breast Cancer", University of Colorado Cancer Center, Aurora, CO
- 2017 Integrated Organ Systems 6 PHRD 6750 Pharmacology Student Lecture, "Introduction to Breast Cancer" University of Colorado School of Pharmacy, Aurora, CO
- 2016 Cancer Research Summer Fellowship Program Lecture, "Breast Cancer", University of Colorado Cancer Center, Aurora, CO
- 2016 Molecular Cancer Course, "Breast Cancer", University of Colorado, School of Medicine, Aurora, CO
- 2016 Radiation Oncology Resident Education, "Breast Cancer Biologics and Clinical Trials", University of Colorado, School of Medicine, Aurora, CO
- 2016 Oncology Fellows Lecture, "Triple Negative Breast Cancer", University of Colorado, School of Medicine, Aurora, CO



- 2016 Integrated Organ Systems 6 PHRD 6750 Pharmacology Student Lecture, "Introduction to Clinical Treatment of Patients with Breast Cancer" University of Colorado School of Pharmacy, Aurora, CO
- 2015 Cancer Research Summer Fellowship Program Lecture, "Breast Cancer", University of Colorado Cancer Center, Aurora, CO
- 2015 Oncology Fellows Lecture, "Triple Negative Breast Cancer", University of Colorado, School of Medicine, Aurora, CO
- 2015 Integrated Organ Systems 6 PHRD 6750 Pharmacology Student Lecture, "Introduction to Clinical Treatment of Patients with Breast Cancer" University of Colorado School of Pharmacy, Aurora, CO
- 2014 Molecular Cancer Course, "Triple Negative Breast Cancer", University of Colorado, School of Medicine, Aurora, CO
- 2014 Oncology Fellows Lecture, "Triple Negative Breast Cancer", University of Colorado, School of Medicine, Aurora, CO
- 2014 Integrated Organ Systems 6 PHRD 6750 Pharmacology Student Lecture, "Introduction to Clinical Treatment of Patients with Breast Cancer", University of Colorado School of Pharmacy, Aurora, CO
- 2013 Cancer Research Summer Fellowship Program Lecture, "Breast Cancer", University of Colorado Cancer Center, Aurora, CO
- 2013 Molecular Cancer Course, "Breast Cancer", University of Colorado, School of Medicine, Aurora, CO
- 2013 Integrated Organ Systems 6 PHRD 6750 Pharmacology Student Lecture, "Introduction to Clinical Treatment of Patients with Breast Cancer" University of Colorado School of Pharmacy, Aurora, CO
- 2013 Internal Medicine Resident Seminar, "Breast Cancer", University of Colorado, School of Medicine, Aurora, CO
- 2013 Radiation Oncology Resident Education, "An Update on Systemic Therapy for Breast Cancer", University of Colorado, School of Medicine, Aurora, CO
- 2013 Oncology Fellows Lecture, "Triple Negative Breast Cancer", University of Colorado, School of Medicine, Aurora, CO
- 2012 Cancer Research Summer Fellowship Program Lecture, "Breast Cancer", University of Colorado Cancer Center, Aurora, CO
- 2012 Internal Medicine Resident Seminar, "Breast Cancer", University of Colorado, School of Medicine, Aurora, CO

- 2012 Integrated Organ Systems 6 PHRD 6750 Pharmacology Student Lecture, "Introduction to Clinical Treatment of Patients with Breast Cancer", University of Colorado School of Pharmacy, Aurora, CO
- 2012 Oncology Fellows Lecture, "Triple Negative Breast Cancer", University of Colorado, School of Medicine, Aurora, CO
- 2012 Radiation Oncology Resident Education, "An Update on Systemic Therapy for Breast Cancer", University of Colorado, School of Medicine, Aurora, CO
- 2011 Cancer Research Summer Fellowship Program Lecture, "Breast Cancer", University of Colorado Cancer Center, Aurora, CO
- 2011 Molecular Cancer Course, "Breast Cancer", University of Colorado, School of Medicine, Aurora, CO
- 2011 Integrated Organ Systems 6 PHRD 6750 Pharmacology Student Lecture, "Introduction to Breast Cancer", University of Colorado School of Pharmacy, Aurora, CO
- 2011 Internal Medicine Resident Seminar, "Adjuvant Treatment of Early Stage Breast Cancer", University of Colorado, School of Medicine, Aurora, CO
- 2011 Oncology Fellows Lecture, "Triple Negative Breast Cancer", University of Colorado, School of Medicine, Aurora, CO
- 2011 Radiation Oncology Resident Education, "An Update on Systemic Therapy for Breast Cancer", University of Colorado, School of Medicine, Aurora, CO
- 2010 Integrated Organ Systems 6 PHRD 6750 Pharmacology Student Lecture, "Introduction to Clinical Management of Breast Cancer", University of Colorado School of Pharmacy, Aurora, CO
- 2010 Oncology Fellows Lecture, "Breast Cancer Clinical Overview", University of Colorado, School of Medicine, Aurora, CO
- 2010 Gynecologic Oncology Fellows Lecture, "Targeted Agents for the Treatment of Ovarian Cancer", University of Colorado, School of Medicine, Aurora, CO

**Conference Faculty and CME Education Program Roles**

- 2023 Mountain States Cancer Conference (CME), Aurora, CO  
Faculty and Speaker
- 2023 Best of ASCO (CME), Scottsdale, AZ  
Faculty and Speaker
- 2023 MLS Oncology (CME), Denver, CO  
Faculty and Speaker
- 2022 San Antonio Breast Cancer Update (CME), National Virtual Meeting

	Planning Committee Member and Speaker
2022	Onc Live Breast Cancer Update (CME), Denver, CO Faculty and Speaker
2021	ESMO and San Antonio Breast Cancer Update (CME), Denver, CO Planning Committee Member and Speaker
2020	ESMO and San Antonio Breast Cancer Update (CME), Denver, CO Planning Committee Member and Speaker
2020	EMPOWER: Optimizing the Paradigm Shift Driven by CDK4/6 Inhibition in Metastatic HR-Positive, HER2-negative Breast Cancer, national series of grand rounds hosted in VA Hospitals and Academic/Community hospitals, USA Faculty and Speaker
2018	A 3-D View of Novel Targeted Agents in Metastatic, Hormone-Receptor Positive, HER-2 Negative Breast Cancer, Grand Rounds series (CME), national series of grand rounds hosted in VA Hospitals and Academic/Community hospitals, USA Faculty and Speaker
2017	American Radium Society 99 <sup>th</sup> Annual Meeting (CME), Colorado Springs, CO Faculty and Speaker
2015	Society of Utah Medical Oncologists Fall Meeting, Park City, UT Faculty and Speaker
2014	Mountain States Cancer Conference (CME), Aurora, CO Conference Chair and Speaker
2013	The Breast Cancer Journey, National Nursing Education Program (CME) Faculty and Speaker
2013	Mountain States Cancer Conference (CME), Aurora, CO Faculty and Speaker
2012	48 <sup>th</sup> Annual Internal Medicine Review Program (CME), Estes Park, CO Faculty and Speaker
2012	Western Slope Oncology Conference, Montrose, CO Faculty and Speaker
2011-2012	Women's Health Research Day, University of Colorado Anschutz Medical Campus Faculty
2010	Mountain States Cancer Conference, Aurora, CO Faculty and Speaker
2009	International Symposium on Anti-Angiogenic Agents, La Jolla, CA Faculty and Speaker

### **Leadership Roles**

2021-Present Program Director, Developmental Therapeutics Fellowship training program  
University of Colorado School of Medicine  
Responsibilities: Curriculum development and training for Medical Oncology fellows seeking specialized training in developmental therapeutics.

### **Clinic and Consult Service Attending**

2010-Present Medical Oncology service attending 2-4 weeks a year, supervision and bedside teaching of fellows, inpatient oncology consult service

2010-Present Breast Oncology clinic attending 10 hours/week, supervision of medical students, residents and fellows

## **BIBLIOGRAPHY**

### **PUBLICATION METRICS (AS OF July 10, 2024)**

Google Scholar citations: **5264**

Google Scholar h-index (largest number h such that h publications have at least h citations): **32**.

Google Scholar i10-index (number of publications with at least 10 citations): **72**.

### **List of Publications**

#### **Original Research: Peer Reviewed**

1. Weinstein R, Eleid N, LeCesne C, Durando B, Crawford JT, Heffner M, Layton C, O'Keefe M, **(Diamond) Robinson J**, Rudinsky S, Henriksen EJ, Tischler ME. Differential Half-Maximal Effects of Human Insulin and Its Analogs for In Situ Glucose Transport and Protein Synthesis in Rat Soleus Muscle. *Metabolism* 2002;51:1065-1070 ([PMID: 12145783](#)).
2. **Diamond JR**, Finlayson C, Borges VF. Hepatic Complications of Breast Cancer. *Lancet Oncology* 2009;10:615-621 ([PMID: 19482250](#)).
3. Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, Hasebroock KM, Pitts TM, **Diamond JR**, Fletcher GC, Bray MR, Eckhardt SG. Assessment of the *in vivo* antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. *Clin Cancer Res* 2010;16:2989-98 ([PMID: 20406842](#)).
4. **Diamond JR**, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak E, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, Morrow M, Arnott J, Bray MR, Sidor CF, Messersmith WA, Shapiro GI. Phase I safety, pharmacokinetic and pharmacodynamic study of ENMD-2076, a novel angiogenic and aurora kinase inhibitor, in patients with advanced solid tumors. *Clin Cancer Res* 2011;17:849-860 ([PMID: 21131552](#)).
5. **Diamond JR**, Salgia R, Varella-Garcia M, Kanteti R, LoRusso P, Clark JW, Xu LG, Wilner K, Eckhardt SG, Ching KA, Lira ME, Schoenmakers EF, Christensen JG, Camidge DR. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. *J Clin Oncol* 2013; 31:e254-8 ([PMID: 23610116](#)).

6. **Diamond JR**, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, Fletcher GC, Tentler JJ. Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models. *Clin Cancer Res* 2013; 19:291-303 ([PMID: 23136197](#)) (**Cover Feature**).
7. Kim Y, Guntupalli SR, Lee SJ, Behbakht K, Theodorescu D, Lee JK, **Diamond JR**. Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer. *PLoS One* 2014; 9:e86532 ([PMID: 24505259](#)).
8. Bowles DW, **Diamond JR**, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Vogler BW, Keysar SB, Freas E, Aisner D, Ren C, Tan AC, Wilhelm F, Maniar M, Eckhardt SG, Messersmith WA, Jimeno A. Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. *Clin Cancer Res* 2014;20:1656-65 ([PMID: 24493827](#)).
9. Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, **Diamond JR**, Kavanagh B, Kabos P. Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. *Neuro Oncol* 2014;16:1006-9 ([PMID: 24497407](#)).
10. Ryall KA, Kim J, Klauck PJ, Shin J, Yoo M, Ionkina A, Pitts TM, Tentler JJ, **Diamond JR**, Eckhardt S, Heasley LE, Kang J, Tan AC. An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. *BMC Genomics* 2015;16 Suppl 12; S2 ([PMID: 26681397](#)).
11. Tentler JJ, Ionkina A, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, **Diamond JR**. p53 family members regulate phenotypic response to Aurora kinase A inhibition in triple-negative breast cancer. *Mol Cancer Ther* 2015;14:1117-1129 ([PMID: 25758253](#)).
12. **Diamond JR**, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. *Invest New Drug* 2015;33:691-699 ([PMID: 25895965](#)).
13. Chiorean EG, LoRusso PM, Strother RM, **Diamond JR**, Younger A, Messersmith WA, Adriaens L, Liu L, Kao RJ, DiCioccio T, Kostic A, Leek R, Harris A, Jimeno A. A phase I first-in-human study of enoticumab (REGN421), a fully-human Delta-like ligand 4 (Dl4) monoclonal antibody in patients with advanced solid tumors. *Clin Cancer Res* 2015;21:2695-2703 ([PMID: 25724527](#)).
14. Pitts, T, Bradshaw-Pierce E, Bagby S, Hyatt S, Selby H, Spreafico A, Tentler J, McPhillips K, Klauck P, Capasso A, **Diamond JR**, Davis SL, Tan AC, Arcaroli J, Purkey A, Messersmith WA, Ecsedy J, Eckhardt SG. Antitumor activity of the Aurora A selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. *Oncotarget* 2016;7:50290-50301. ([PMID: 27385211](#))
15. Weekes CD, Lamberts LE, Borad M, Voortman J, McWilliams R, **Diamond JR**, de Vries EGE, Verheul HMW, Lieu HC, Kim GP, Want Y, Scales SJ, Samineni D, Brunstein F,

- Maslyar DJ, Colon-Otero G. Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. *Mol Cancer Ther* 2016: 15;439-447 ([PMID: 26823490](#)).
16. Park JW, Liu MC, Yee D, Yau C, van't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators (**Diamond J**). Adaptive randomization of neratinib in early breast cancer. *N Engl J Med* 2016: 375;11-22 ([PMID 27406346](#)).
17. Rugo HS, Olopade OI, DeMichele A, Yau C, van't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators (**Diamond J**). Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. *N Engl J Med* 2016: 375;23-34 ([PMID: 27406347](#)).
18. Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, **Diamond JR**, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly x 2 every-3-week schedule. *Invest New Drugs* 2017 epub ahead of print ([PMID: 28105566](#)).
19. Bardia A, Mayer IA, **Diamond JR**, Moroosse RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT. Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. *J Clin Oncol* 2017 ([PMID: 28291390](#)).
20. **Diamond JR**, Goff B, Forster MD, Bendell JC, Britten CD, Gordon MS, Gabra H, Waterhouse DM, Poole M, Ross Camidge D, Hamilton E, Moore KM. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers. *Invest New Drugs* 2017 ([PMID: 28283779](#)).
21. Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, Eckhardt SG, **Diamond JR**. Efficacy and molecular mechanisms of differentiated response to the Aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical models of p53-mutated triple-negative breast cancer. *Front Oncol* 2017 15:7 ([PMID: 28555173](#)).
22. **Diamond JR**, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. A phase II clinical trial of the Aurora and angiogenic

- kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. *Breast Cancer Res* 2018 ([PMID: 30071865](#)).
23. Capasso A, Pitts TM, Klauck PJ, Bagby SM, Westbrook L, Kaplan L, Soleimani M, Spreafico A, Tentler JJ, **Diamond JR**, Arcaroli JJ, Messersmith WA, Eckhardt SG, Leong S. Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models. *Anticancer Drugs* 2018 ([PMID: 30048249](#)).
24. Davis SL, Eckhardt SG, **Diamond JR**, Messersmith WA, Dasari A, Weekes CD, Lieu CH, Kane M, Choon Tan A, Pitts TM, Leong S. A Phase I dose-escalation study of linsitinib (OSI-906), a small-molecule dual insulin-like growth factor-1 receptor/insulin receptor kinase inhibitor, in combination with irinotecan in patients with advanced cancer. *Oncologist* 2018 ([PMID: 30139840](#)).
25. Jimeno A, Moore KN, Gordon M, Chugh R, **Diamond JR**, Aljumaily R, Mendelson D, Kapoun AM, Xu L, Stagg R, Smith DC. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. *Invest New Drugs*. 2019 ([PMID 30229512](#)).
26. Adams S, **Diamond JR**, Hamilton E, Pohlmann, PR, Tolaney SM, Chang C, Zhang W, Iizuka K, Foster PG, Molinero L, Funke R, Powderly J. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up. *JAMA Oncol* 2019 ([PMID: 30347025](#)).
27. Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, **Diamond JR**, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob B, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. *Journal of Immunotherapy of Cancer* 2019 ([PMID: 30736857](#)).
28. Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, **Diamond JR**, O'Shaughnessy J, Moroosse RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Sacituzumab govitecan-hziy for refractory metastatic triple negative breast cancer. *NEJM* 2019 ([PMID: 30786188](#)).
29. Stumpf PK, Cittelly DM, Robin TP, Carlson JA, Stuhr KA, Contreras-Zarate MJ, Lai S, Ormond DR, Rusthoven CG, Gaspar LE, Rabinovitch R, Kavanagh BD, Liu A, **Diamond JR**, Kabos P, Fisher CM. Combination of trastuzumab emtansine and stereotactic radiosurgery results in high rates of clinically significant radionecrosis and dysregulation of aquaporin-4. *Clin Cancer Res* 2019 ([PMID: 30940654](#)).
30. Capasso A, Dailey KL, Currimjee N, Yacob B, Ionkina A, Frank JG, Kim DJ, George C, Lee YB, Benaim E, Tan AC, Kim J, Pitts TM, Eckhardt SG, Tentler JJ, **Diamond JR**. First-in-class phosphorylated-p68 inhibitor RX-5902 inhibits B-catenin signaling and demonstrates anti-tumor activity in triple-negative breast cancer. *Mol Cancer Ther* 2019 ([PMID: 31488700](#)).
31. Davis SL, Ionkina A, Bagby SM, Orth J, Lam ET, Corr BR, O'Bryant CL, Glode A, Tenter JJ, Capasso A, Dailey KL, Serkova NJ, Weekes CD, Gustafson DL, Messersmith WA, Leong S, Eckhardt SG, Pitts TM, **Diamond JR**. Preclinical and dose-finding phase I trial



- results of combined treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. Clin Cancer Res 2020, ([PMID: 32414750](#)).
32. Arasu VA, Kim P, Li W, Strand F, McHargue C, Harnish R, Newitt DC, Jones EF, Glymour MM, Kornak J, Esserman LJ, Hylton NM; ISPY2 Investigators (**Diamond JR**). Predictive value of breast MRI background parenchymal enhancement for neoadjuvant treatment response among HER2- patients. J Breast Imaging 2020 (PMID: 32803155).
33. Pitts TM, Simmons DM, Bagby SM, Hartman SJ, Yacob BW, Gittleman B, Tentler JJ, Cittelly D, Ormond DR, Messersmith WA, Eckhardt SG, **Diamond JR**. Wee1 inhibition enhances the anti-tumor effects of capecitabine in preclinical models of triple-negative breast cancer. Cancers 2020 ([PMID: 32204315](#)).
34. Corr BR, Moroney M, Sheeder J, Eckhardt SG, Sawyer B, Behbakht K, **Diamond JR**. Survival and clinical outcomes of patients with ovarian cancer who were treated on phase I clinical trials. Cancer 2020 ([PMID: 32697381](#)).
35. Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P, KEYNOTE-355 Investigators (**Diamond JR**). Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomized, placebo-controlled, double-blind, phase 3 trial. Lancet 2020 ([PMID: 33278935](#)).
36. Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J, KEYNOTE-522 Investigators (**Diamond JR**). Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020 ([PMID: 32101663](#)).
37. **Diamond JR**, Becerra C, Richards D, Mita A, Osborne C, O'Shaughnessy J, Zhang C, Henner R, Kapoun AM, Xu L, Stagg B, Uttamsingh S, Brachmann RK, Farooki A, Mita M. Phase Ib clinical trial of the anti-frizzled antibody vanttumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020 ([PMID: 32803633](#)).
38. Sakamoto MR, Eguchi M, Azelby CM, **Diamond JR**, Fisher CM, Borges VF, Bradley CJ, Kabos P. New opioid and benzodiazepine use after curative-intent treatment in breast cancer patients. JNCCN 2021 ([PMID: 33406490](#)).
39. Tentler J, Lang J, Capasso A, Kim DJ, Benaim E, Lee YB, Eisen A, Bagby SM, Hartman SJ, Yacob BW, Gittleman B, Pitts TM, Palanda R, Eckhardt SG, **Diamond JR**. RX-5902, a novel B-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast cancer. BMC Cancer 2020 ([PMID: 33148223](#)).
40. Weiss JA, Nicklawsky A, Kagihara JA, Gao D, Fisher C, Elias A, Borges VF, Kabos P, Davis SL, Leong S, Eckhardt SG, **Diamond JR**. Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center. Cancer Medicine 2020 ([PMID: 33063469](#)).



41. Kalinsky K, **Diamond JR**, Vahdat LT, Tolaney SM, Juric D, O'Shaughnessy J, Moroosse RL, Mayer IA, Abramson VG, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Goswami T, Wegener WA, Bardia A. Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial. *Annals of Onc* 2020 ([PMID: 32946924](#)).
42. Ma WW, Zhu M, Lam ET, **Diamond JR**, Dy GK, Fisher GA, Goff LW, Alberts S, Bui L, Sanghal A, Kothekar M, Khopade A, Chimote G, Faulkner R, Eckhardt SG, Adjei AA, Jimeno A. A Phase I pharmacokinetic and safety study of paclitaxel injection concentrate for nano-dispersion (PICN) alone and in combination with carboplatin in subjects with advanced solid malignancies and biliary tract cancers. *Ca Chemo Pharm* 2021 ([PMID: 33634324](#)).
43. Stoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, **Diamond JR**. Real-world evidence from a university hospital system regarding the use of adjuvant pertuzumab and/or neratinib before and after their FDA approvals. *Breast Cancer Res Treat*. 2021 ([PMID: 33625615](#)).
44. Schreiber AR, Kagihara JA, Weiss JA, Nicklawsky A, Gao D, Borges VF, Kabos P, **Diamond JR**. Clinical outcomes for patients with metastatic breast cancer treated with immunotherapy agents in phase I clinical trials. *Front Oncol* 2021 ([PMID: 33816286](#)).
45. Lim B, Potter DA, Salkeni MA, Silverman P, Haddad T, Forget F, Awada A, Canon JL, Danso M, Lortholary A, Bourgeois H, Tan-Chiu E, Vincent S, Bahamon B, Kalinsky K, Patel C, Neuwirth R, Leonard EJ, **Diamond JR**. Sapanisertib plus exemestane or fulvestrant in women with hormone receptor-positive/HER2-negative advanced or metastatic breast cancer. *Clin Cancer Res* 2021 ([PMID: 33820779](#)).
46. Atrafi F, Boix O, Subbiah V, **Diamond JR**, Chawla S, Tolcher AW, LoRusso P, Eder JP, Gutierrez M, Sankhala K, Rajagopalan P, Genvresse I, Langer S, Mathijssen RH, Verweij J, Bruns I, Lolkema MP. A phase 1 study of an MPS-1 inhibitor (BAY 1217389) in combination with paclitaxel using a novel randomized continual reassessment method for dose escalation. *Clin Cancer Res* 2021 ([PMID: 34518310](#)).
47. Marin-Jimenez JA, Capasso A, Lewis MS, Bagby SM, Hartman SJ, Shulman J, Navarro NM, Yu H, Rivard CJ, Wang X, Barkow JC, Geng D, Kar A, Yingst A, Tufa DM, Dolan JT, Blatchford PJ, Freed BM, Torres RM, Davila E, Slansky JE, Pelanda R, Eckhardt SG, Messersmith WA, **Diamond JR**, Lieu CH, Verneris MR, Wang JH, Kiseljick-Vassiliades K, Pitts TM, Lang J. Testing cancer immunotherapy in a human immune system mouse model: correlating treatment responses to human chimerism, therapeutic variables and immune cell phenotypes. *Front Immunol* 2021 ([PMID: 33854497](#)).
48. Hartman SJ, Bagby SM, Yacob BW, Simmons DM, MacBeth M, Lieu CH, Davis SL, Leal AD, Tentler JJ, **Diamond JR**, Eckhardt SG, Messersmith WA, Pitts TM. WEE1 inhibition in combination with targeted agents and standard chemotherapy in preclinical models of pancreatic models of pancreatic ductal adenocarcinoma. *Front Oncol* 2021 ([PMID: 33869031](#)).
49. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S,

- Cortes J, O'Shaughnessy J, Dieras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Hugo HS; ASCENT Clinical Trial Investigators (**Diamond JR**). Sacituzumab govitecan in metastatic triple-negative breast cancer. *NEJM* 2021 ([PMID: 33882206](#)).
50. Gonzalez-Ericsson PI, Wulfhule JD, Gallagher RI, Sun X, Axelrod ML, Sheng Q, Luo N, Gomez H, Sanchez V, Sanders M, Pusztai L, Petricoin E, Blenman KRM, Balko JM, I-SPY2 Trial Team (**Diamond JR**). Tumor-specific major histocompatibility-II expression predicts benefit to Anti-PD-1/L1 therapies in patients with HER2-negative primary breast cancer. *Clin Cancer Res* 2021 ([PMID: 34315723](#)).
51. Schreiber AR, Kagihara J, Eguchi M, Kabos P, Fisher CM, Meyer E, Molina E, Kondapalli L, Bradley CJ, **Diamond JR**. Evaluating Anthracycline + Taxane versus Taxane-Based Chemotherapy in Older Women with Node-Negative Triple-Negative Breast Cancer: a SEER-Medicare Study. *Breast Cancer Research Treat* 2021 ([PMID: 34705147](#)).
52. Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 investigators (**Diamond JR**). Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. *NEJM* 2022 ([PMID: 35857659](#)).
53. Marczyk M, Mrukwa A, Yau C, et al; I-SPY Consortium (**Diamond JR**). Treatment efficacy score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. *Ann Oncol* 2022 ([PMID: 35513244](#)).
54. **Diamond JR**, Boni V, Lim E, Nowakowski G, Cordoba R, Morillo D, Valencia R, Genvresse I, Merz C, Boix O, Frigault MM, Greer JM, Hamdy AM, Huang X, Izumi R, Wong H, Moreno V. First-in-human dose escalation study of cyclin-dependent kinase-9 inhibitor VIP152 in patients with advanced malignancies shows early signs of clinical efficacy. *Clin Cancer Res* 2022 ([PMID: 35046056](#)).
55. **Diamond JR**, Pitts TM, Ungermannova D, Nasveschuk CG, Zhang G, Phillips AJ, Bagby SM, Pafford J, Yacob BW, Newton TP, Tentler JJ, Gittleman B, Hartman SJ, DeMattei JA, Winkler JD, Wendt MK, Schiemann WP, Eckhardt SG, Liu X, Piscopio AD. Preclinical development of the class I selective histone deacetylase inhibitor OKI-179 for the treatment of solid tumors. *Mol Cancer Ther* 2022 ([PMID: 3496595](#)).
56. Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kumel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators (**Diamond JR**). Event-free survival with Pembrolizumab in early triple-negative breast cancer. *NEJM* 2022 ([PMID: 35139274](#)).
57. Carey LA, Loirat D, Punie K, Bardia A, Dieras V, Dalenc F, **Diamond JR**, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, O'Shaughnessy J, Loibl S, Gianni L, Piccart M, Zhu Y, Delaney R, Phan S, Cortes J. Assessment of Sacituzumab govitecan as second-line treatment in patients with metastatic triple-negative breast cancer: A

- subgroup analysis of the Phase 3 ASCENT study. NPJ Breast 2022 ([PMID: 35680967](#)).
58. Ma WW, Li JJ, Azad NS, Lam ET, **Diamond JR**, Dy GK, Opyrchal M, Zhi J, Kramer D, Chan WK, Cutler D, Kwan R, Adjei AA, Jimeno A. A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies. Cancer Chemother Pharmacol 2022 ([PMID: 35731258](#)).
59. Boland PM, Fountzilas C, Fakih M, Opyrchal M, **Diamond JR**, Corr B, Ma WW, Redman M, Chan W, Wang H, Kramer D, Kwan R, Cutler D, Jimeno A. A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies. Cancer Chemother Pharmacol 2022 ([PMID: 35904620](#)).
60. Hilton J, Cristea M, Postel-Vinay S, Baldini C, Voskoboynik M, Edenfield W, Shapiro GI, Cheng ML, Vuky J, Borr B, Das S, Apfel A, Xu K, Kozicki M, Unsal-Kacmaz K, Hammell A, Wang G, Ravindran P, Kollia G, Esposito O, Coker S, **Diamond JR**. BMS-986158, a small molecule inhibitor of the bromodomain and extraterminal domain proteins, in patients with selected advanced solid tumors: Results from a phase 1/2a trial. Cancers 2022 ([PMID: 36077617](#)).
61. Davis SL, Hartman SJ, Bagby SM, Schlaepfer M, Yacob BW, Tse T, Simmons DM, **Diamond JR**, Lieu CH, Leal AD, Cadogen EB, Hughes GD, Durant ST, Messersmith WA, Pitts TM. ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer. BMC Cancer 2022 ([PMID: 36309653](#)).
62. Roy S, Lakritz S, Schreiber AR, Molina E, Kabos P, Wood M, Elias A, Kondapalli L, Bradley CJ, **Diamond JR**. Clinical outcomes of adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study. Eur J Cancer 2023 ([PMID: 36965330](#)).
63. Cheng ML, Huang Y, Luong N, LoPiccolo J, Nishino M, Sholl LM, Chirieac LR, Santucci AD, Rabin MS, Janne PA, Coker S, **Diamond JR**, Hilton J, Shapiro GI, French CA. Exceptional response to BET bromodomain inhibitor therapy with BMS-986158 associated with BRD4 splice site mutation in BRD4-NUTM1 NUT carcinoma. JCO precision oncology 2023 ([PMID: 37384867](#)).
64. Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges V, Kabos P, **Diamond JR**, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, Zolman KL, von Bokhoven A, Zhuang Y, Wulfkuhle J, Petricoin E, Gao D, Richer JK. Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer. NPJ Breast Ca 2023 ([PMID: 37210417](#)).
65. Shagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner AJ, Stopeck A, Parris H, Gao D, McSpadden T, Mayordomo J, **Diamond JR**, Kabos P, Borges VF. Safety and efficacy of tucatinib, Palbociclib and letrozole in patients with previously treated HR+/HER2+ breast cancer. Clin Cancer Res 2023 ([PMID: 37363965](#)).
66. Triplett TA, Holay N, Somma A, Duchow M, Soleimani M, Capasso A, Kotapalli S, Rios J, Giri U, **Diamond J**, Schreiber A, Piscopio AD, Van Den Berg C, Eckhardt SG.

Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy. *Front Immunol* 2023 ([PMID: 37744352](#)).

67. Schreiber AR, Kagihara JA, Corr BR, Davis SL, Lieu C, Kim S, Jimeno A, Camidge DR, Williams J, Heim AM, Martin A, DeMattei JA, Holay N, Triplett TA, Eckhardt SG, Litwiler K, Winkler J, Piscopio AD, **Diamond JR**. First-in-human dose-escalation study of the novel oral depsipeptide class I-targeting HDAC inhibitor bocodepsin (OKI-179) in patients with advanced solid tumors. *Cancers* 2023 ([PMID: 38201519](#)).
68. Patel SP, Gordo TA, Banerjee S, Wang D, Naidoo J, Standifer NE, Palmer DC, Cheng LY, Kourtesis P, Ascierto ML, Das M, **Diamond JR**, Hellman MD, Carneiro BA. Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. *J Immunotherapy Cancer* 2024 ([PMID: 38309722](#)).
69. Roy S, Lakritz S, Schreiber AR, Molina E, Bradley CJ, Kondapalli L, **Diamond JR**. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane+anthracycline versus taxane-based chemotherapy regimens: A SEER-Medicare study. *Eur J Cancer* 2024 ([PMID: 38000217](#)).
70. Smoots SG, Schreiber AR, Jackson MM, Bagby SM, Dominguez ATA, Dus ED, Binns CA, **Diamond JR**, Pitts TM. Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin to promote apoptosis. *Breast Cancer Res* 2024 ([PMID: 38429789](#)).
71. Davis SL, Messersmith WA, Purcell WT, Lam ET, Corr BR, Leal AD, Lieu CH, O'Bryant CL, Smoots SG, Dus ED, Serkova NJ, Pitts TM, **Diamond JR**. A phase Ib expansion cohort evaluating Aurora A kinase inhibitor alisertib and dual TORC1/2 inhibitor sapanisertib in patients with advanced solid tumors. *Cancers* 2024 ([PMID: 38672538](#)).
72. Elias AD, Staley A, Fornier M, Vidal GA, Alami V, Sams S, Spoelstra N, Goodspeed A, Kabos P, **Diamond JR**, Shagisultanova E, Gallagher RI, Wulfschuhle J, Petricoin E, Zolman K, McSpadden T, Jordan KR, Slansky JE, Borges VF, Gao D, Richer JK. Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/HER2- primary breast cancer: Effects on tumor immune microenvironment and clinical outcomes. *NPJ Breast Cancer* 2024 ([PMID: 39368973](#)).
73. Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kumel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Im SA, Untch M, Fasching PA, Mouret-Reynier MA, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O'Shaughnessy J; KEYNOTE-522 Investigators (**Diamond JR**). Overall survival with pembrolizumab in early-stage triple-negative breast cancer. *NEJM* 2024 ([PMID: 39282906](#)).
74. Giordano A, Awan AA, Bruce JY, Rugo HS, **Diamond JR**, Novik Y, Baranda J, Muro K, Ono M, Nanda R, Kaplan J, Gorla S, Liu S, Wozniak M, Poondru S, Dillon R, Ment C, Traina T. Enfortumab vedotin in patients with previously treated advanced breast cancer in the Phase 2 EV-202 study. *JCO Oncology Advances* 2025.
75. Robin TP, Hu J, Jones BL, Patton T, **Diamond JR**, Behbakht K, Lefkowitz C, Corr BR, Fisher CM. Phase I trial of stereotactic body radiation therapy (SBRT) for limited site

locoregional recurrences of ovarian cancer. *Gynecologic Oncology* 2025.

76. Alsafar A, Kareem SL, Corr BR, Lieu CH, Wilky B, Davis SL, Camidge DR, Jimeno A, Messersmith WA, Nicklawsky A, Pacheco D, Borraya EA, McDermott JD, **Diamond JR**. Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center. *Front Oncol* 2025 (PMID: 40735038).
77. Shagisultanova E, Parris H, Liu L, Giangliuli S, Gao D, **Diamond JD**, Acharya-Leon R, Kabos P, Borges VF. Sequential therapy with HER2 tyrosine kinase inhibitors in patients with HER2-positive metastatic breast cancer. *Clin Breast Cancer* 2025 (PMID: 40610321).
78. Schreiber AR, Smoots SG, Jackson MM, Bagby SM, Dus ED, Dominguez ATA, Binns CA, Pitts TM, **Diamond JR**. Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. *Front Oncol* 2025 (PMID: 40242242).
79. Sottnik JL, Shackleford MT, Nesiba CS, Richer AL, Fleischmann Z, Swartz JM, Rowland CE, Musick M, Fu R, Myler LR, Opresko PL, Mehrotra S, Sokol ES, Hesselberth JR, **Diamond JR**, Sikora MJ. Co-regulator activity of mediator of DNA damage checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast. *bioRxiv* 2025 (PMID: 39677775).

#### **Invited Reviews and Case Reports: Peer Reviewed**

80. **Diamond JR**, Borges VF, Eckhardt SG, Jimeno A. BRCA in breast cancer: from risk assessment to therapeutic prediction. *Drug News Perspect* 2009;22;603-608 ([PMID: 20140280](#)).
81. **Diamond JR**, Finlayson CA, Thienelt C, Kabos P, Hardesty L, Barbour L, Klein C, Rabinovitch R, Elias A, Borges VF. Early stage BRCA-2 associated breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state. *Oncology* 2009;23;784-791 ([PMID: 19777765](#)).
82. Kounalakis N, **Diamond J**, Rusthoven K, Horn W, Jindal S, Wisell J, Klein C, Elias A, Finlayson C, Borges VF. A young women presenting with pleomorphic lobular carcinoma in situ on core biopsy is subsequently diagnosed with invasive lobular carcinoma. *Oncology* 2011; 25;351-356 ([PMID: 21618957](#)).
83. Harry BL, Smith ML, Burton JR, Dasari A, Eckhardt SG, **Diamond JR**. Medullary thyroid cancer and pseudocirrhosis: case report and literature review. *Current Oncology* 2012;19;e36-41 ([PMID: 22328846](#)).
84. Lieu CH, **Diamond JR**, Leong S, Eckhardt SG. From bench to bedside: Assessing the impact of preclinical studies on targeted agent development in oncology. *J Natl Cancer Inst* 2013; 105;1441-56 ([PMID: 24052618](#)).
85. **Diamond JR**, Elias AD. [The development of targeted therapies for triple-negative breast cancer: Can we harness tumor heterogeneity to improve patient outcomes.](#) *Breast Cancer Management* 2013; 2;175-178.



86. Fisher CM, **Diamond JR**, Kounalakis N, Kabos P, Mayordomo J, Rabinovitch R, Murphy C, Finlayson C, Borges VF, Elias AD. [The integration of locoregional with systemic adjuvant therapy for early-stage breast cancer: the shifting sands of decision-making.](#) Breast Cancer Manag 2014: 3;205-212.
87. Davis SL, Eckhardt SG, Tentler JJ, **Diamond JR**. Triple-Negative Breast Cancer: bridging the gap from cancer genomics to predictive biomarkers. Ther Adv Med Oncol 2014: 6;88-100 ([PMID: 24790649](#)).
88. Owsley J, Jimeno A, **Diamond JR**. Palbociclib: CDK4/6 inhibition in the treatment of ER-positive breast cancer. Drugs of Today 2016: 52;119-129 ([PMID: 27092341](#)).
89. Overholser L, Shagisultanova E, Rabinovitch R, Kounalakis N, **Diamond J**, Finlayson C, Fisher C, Kabos P, Elias A, Borges VF, Mayordomo J. Breast cancer following radiation for Hodgkin Lymphoma: Clinical scenarios and risk-reducing strategies. Oncology 2016: 15;1063-1070 ([PMID: 27987198](#)).
90. Stoen E, Kabos P, Borden KC, Brown RJ, Borges VF, **Diamond JR**. A 35-year old woman with a change in HER2 expression following neoadjuvant chemotherapy for invasive breast cancer. Oncology 2018 ([PMID: 29940061](#)).
91. Weiss J, Afghahi A, Shagisultanova E, **Diamond JR**. Approaching use of CDK4/6 inhibitors in metastatic HR+ HER2- breast cancer. Oncology 2018 ([PMID: 30334242](#)).
92. Weiss J, Glode A, Messersmith W, **Diamond J**. Sacituzumab govitecan: Breakthrough targeted therapy for triple-negative breast cancer. Expert Rev Anticancer Ther 2019 ([PMID: 31398063](#)).
93. Kagihara JA, Andress M, **Diamond JR**. Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. Expert Rev Precision Med and Drug Development 2020, ([PMID: 32190733](#)).
94. Schreiber AR, Andress M, **Diamond JR**. Tackling Metastatic Triple-Negative Breast Cancer with Sacituzumab Govitecan: A Review. Expert Rev Anticancer Ther 2021 ([PMID: 34651524](#)).
95. Kagihara J, Shagisultanova E, Afghahi A, **Diamond JR**. Moving towards targeted therapies for triple-negative breast cancer. Curr Breast Cancer Rep 2021 ([PMID: 34457184](#)).
96. Shay RC, **Diamond JR**, Kagihara JA, Sams SB. Paraneoplastic encephalitis associated with locally advanced human epidermal growth factor 2-positive breast cancer. J Breast Cancer 2021, ([PMID: 33634625](#)).
97. Schreiber A, Kabos P, O'bryant C, **Diamond JR**. The emergence of targeted therapy for HER2-low Triple-Negative Breast Cancer: A review of fam-trastuzumab deruxtecan. Expert Rev Anticancer Ther 2023 ([PMID: 37742278](#)).

**Original Research: Oral Podium Presentations at International Meetings**

1. Jimeno A, LoRusso P, Younger A, **Diamond J**, Plato L, Stroher RM, Messersmith WA, Sawyer DB, Adriaens L, Liu L, Kao R, DiCioccio AT, Brownstein C, Lowy I, Trail P, and Chiorean EG. A phase I first-in-human study of REGN421 (R)/SAR153192, a fully-human Delta-like Ligand 4 (Dl4) monoclonal antibody, in patients with advanced solid tumors. American Society of Clinical Oncology (ASCO) Annual Meeting, Oral Presentation, June 2013.
2. **Diamond JR**, Eckhardt SG, Bendell JC, Munster P, Morris VK, Kopetz S, Cattaruzza F, Kapoun AM, Dupont J, Faoro L. A Phase Ia/b study of OMP-131R10, an anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC). 14<sup>th</sup> International congress on Targeted Anticancer Therapies (TAT), Oral Presentation, March 2016.
3. **Diamond JR**, Tentler JJ, Howison RR, Pitts TM, Kim DJ, Benaim E, Mazhari R, Eckhardt SG. Novel targeted phosphorylated p68 inhibitor RX-5902 shows activity in triple-negative breast cancer. 14<sup>th</sup> International congress on Targeted Anticancer Therapies (TAT), Oral Presentation, March 2016.
4. Hellmann MD, Antonia SJ, Ponce S, Ott PA, Calvo E, Taylor M, Ready N, Hann CL, De Braud F, Eder JP, Jager D, Ascierto PA, Horn L, Amin A, Evans J, Moreno V, Atmaca A, Pillai RN, Bhosle J, Bono P, Reguart N, Schneider J, Brossart P, **Diamond J**, Sharma P, Lassen U, Lin CS, Tschaike M, Selvaggi G, Spigel D. Nivolumab alone or with ipilimumab in recurrent SCLC: 2-year survival and updated analyses from the CheckMate 032 trial. IASLC 17<sup>th</sup> World Conference on Lung Cancer, Oral Presentation, December 2016.
5. Bardia A, Vahdat LT, **Diamond JR**, Kalinsky K, O'Shaughnessy J, Moroos RL, Isakoff SJ, Tolaney SM, Santin AD, Abramson V, Shah NC, Govindan SV, Maliakal P, Sharkey RM, Wegener WA, Goldenberg DM, Mayer IA. Sacituzumab govitecan (IMMU-132), an anti-trop-2-SN-38 antibody-drug conjugate, as > 3<sup>rd</sup>-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): Efficacy results. San Antonio Breast Cancer Symposium (SABCS), Oral Presentation, San Antonio, TX, December 2016.
6. **Diamond JR**, Moreno V, Lim E, Cordoba R, Cai C, Ince S, Lettieri J, Merz C, Valencia R, Boni V. Phase I dose escalation study of the first-in-class selective PTEFb inhibitor BAY1251152 in patients with advanced cancer: Novel target validation and early evidence of clinical activity. American Society of Clinical Oncology (ASCO) Annual Meeting, Oral Presentation, June 2018.
7. Hilton J, Cristea M, Voskoboynik, Postel-Vinay, Edenfield W, Gavai A, Wee S, Srivastava N, Klippel A, Jackson D, Apfel A, Chasalow S, Williams D, Donovan M, Fischer B, Khaldoyanidi S, **Diamond JR**. Initial results from a phase 1/2a trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer. European Society of Medical Oncology (ESMO) Annual Congress, Oral Presentation, October 2018.
8. **Diamond JR**, Gordon G, Kagihara J, Corr B, Lieu C, Pachecho J, Heim AM, DeMattei JA, Eckhardt SG, Winkler J, Piscopio AD. Initial results from a phase I trial of OKI-179, a class I-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors. EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, Spain Virtual Meeting, October 2020.

9. Amaria RN, Duvivier H, Tsai K, Galamaga R, Momtaz P, Pisick E, Langr N, Dave H, Walker D, **Diamond JR**, Litwiler K, Sullivan R. Novel strategy for RAS-pathway targeting: Initial results from a phase 1b/2 clinical trial of the oral HDAC inhibitor bocodepsin (OKI-179) combined with binimetinib in patients with RAS-pathway mutated solid tumors and NRAS-mutated melanoma. Oral Presentation, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston October 2023.
10. Perez CA, Henry JT, Lakhani N, Call J, Hamilton E, Colon-Otero G, **Diamond JR**, O'Neil B, Kalyan A, Sonpavde G, Moreno I, Awan A, Fontana E, Xu P, Zhang F, Nazarenko N, Patnaik A. First-in-human study of SGN-B7H4V, a B7-H4 directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase 1 study (SGNB7H4V-001). Oral Presentation, ESMO Congress Madrid, October 2023.
11. Giordano A, Awan A, Bruce JY, Rugo HS, **Diamond JR**, Novik Y, Baranda J, Muro K, Ono M, Nanda R, Kaplan J, Gorla S, Liu S, Lee A, Traina T. Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202. Oral Abstract Presentation, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, 2024.

#### **Original Research: Poster Presentations at International Meetings**

1. **Diamond JR**, Eckhardt SG, Pitts TM, Britt BC, Kachaeva MI, Varella-Garcia M, Bray MR, Fletcher GC, Tentler JJ. A novel multi-targeted Aurora A and VEGFR2 kinase inhibitor, ENMD-2076, demonstrates synergistic antiproliferative and proapoptotic effects in combination with chemotherapy and trastuzumab in breast cancer cell lines. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Poster Presentation, November 2009.
2. **Diamond JR**, Amaria R, O'Donnell CI, Meltesen L, Swisshelm K, Melancon D, McGavran L, Singh M, Elias A, Borges VF. The incidence of low-level HER2 gene amplification and chromosome 17 polysomy in cases of newly diagnosed breast cancer and their association with clinical prognostic markers. American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2009.
3. Bastos BR, **Diamond J**, Hansen R, Gustafson D, Arnott J, Bray M, Sidor C, Messersmith W, Shapiro G. An open-label, dose escalation, safety, and pharmacokinetic study of ENMD-2076 administered orally to patients with advanced cancer, American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2009.
4. Selby H, Kim J, Tentler T, **Diamond J**, Pitts T, Leong S, Messersmith W, Jimeno A, Eckhardt SG, Tan AC. A strategy to accelerate the development of predictive biomarkers for novel anti-cancer agents. Intelligence Systems for Molecular Biology (ISMB), Poster Presentation, 2010.
5. **Diamond JR**, Eckhardt SG, Tan AC, Selby HM, Newton TP, Pitts TM, Bray MR, Fletcher GC, Tentler JJ. In vitro and in vivo antitumor activity of the Aurora and angiogenic kinase inhibitor ENMD-2076 in triple-negative breast cancer models. San Antonio Breast Cancer Symposium (SABCS), Poster Presentation, December 2011.



6. Bowles D, **Diamond JR**, Lam ET, Messersmith WA, Weekes CD, Leong S, Gore L, Lieu CH, Freas E, Ren C, Wilhelm F, Eckhardt SG, Jimeno A. Phase I study of oral rigosertib in patients with advanced solid tumors. American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2012.
7. Borges VF, Ramirez O, Borakove M, Manthey E, Finlayson C, Elias A, McCarter M, Jordan K, **Diamond J**, Kounalakis N. Young woman's breast cancer demonstrates increased immune suppression through circulating regulatory T cells and myeloid-derived suppressor cells independent of stage or subtype. American Association of Cancer Research (AACR) Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances, Poster Presentation, 2012.
8. **Diamond JR**, Tan AC, Pitts TM, van Bokhoven, A, Aisner D, Elias AD, Borges VF, Miller KD, Eckhardt SG, Tentler JJ. A Phase II Clinical Trial of ENMD-2076 in Metastatic Triple-Negative Breast Cancer: Translating a p53-based Biomarker from Bench to Bedside. International Congress on Targeted Anticancer Therapies (TAT), Poster Presentation, March 2013.
9. Astling D, Cross BR, Tentler JJ, Newton TP, Pitts TM, Gunther E, Liu X, Eckhardt SG, **Diamond JR**. A Novel Class I Histone Deacetylase (HDAC) Inhibitor, Paragazole, Demonstrates Antiproliferative and Proapoptotic Effects in Triple-Negative Breast Cancer Models. American Association of Cancer Research (AACR) Annual Meeting, Poster Presentation, April 2013.
10. Ma WW, Lam E, Dy GK, **Diamond JR**, Zhao Y, Bui L, Fetterly G, Abramowitz W, Harning R, Pencheva P, Bhowmik S, Divekar G, DiRaddo AM, Eckhardt SG, Adjei A, Jimeno A. A pharmacokinetic and dose escalating study of paclitaxel injection concentrate for Nano-Dispersion (PICN) alone and with carboplatin in advanced solid tumor patients. American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2013.
11. Ionkina AA, Tentler JJ, Newton TP, Brunkow KL, Johnson JS, Tan AC, Pitts TM, Eckhardt SG, **Diamond JR**. The role of p53 family tumor suppressors in mediating response to the Aurora and angiogenic kinase inhibitor ENMD-2076 in triple-negative breast cancer. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Poster Presentation, November 2013.
12. **Diamond JR**, Tan AC, Ionkina AA, Newton TP, Pitts TM, Eckhardt SC, Tentler JJ. The role of p53 family tumor suppressors in mediating response to aurora kinase inhibition in triple-negative breast cancer. San Antonio Breast Cancer Symposium (SABCS), Poster Presentation, December 2013.
13. **Diamond JR**, Agarwal N, Bowles DW, Lam ET, Werner TL, Wu B, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S. Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib (AMG386) and paclitaxel (PTX) in patients (pts) with advanced solid tumors. American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2014.
14. Weekes CD, Lamberts LE, Borad M, Voortman J, McWilliams R, **Diamond JR**, de Vries EGE, Verheul H, Lieu C, Yue H, Want Y, Scales SJ, Samineni D, Wood K, Brunstein

- F, Maslyar DJ, Kim GP. A Phase I Study of DMOT4039A, an Antibody-Drug Conjugate (ADC) Targeting Mesothelin (MSLN), in Patients (pts) with Unresectable Pancreatic (PC) or Platinum Resistant Ovarian Cancer (OC). American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2014.
15. Ma WW, **Diamond JR**, Ky GK, Messersmith WA, Zhao Y, Bui LA, Fetterly GJ, Harning R, Wolfe H, Pencheva P, Bhowmik S, Kivekar G, Lakkad NB, Khopade AJ, DiRaddo AM, Eckhardt SG, Adjei AA, Jimeno A. A phase I and pharmacokinetic study of a weekly dosing schedule of Paclitaxel injection concentrate for nano-dispersion (PICN) in patients with advanced solid tumors. American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2014.
16. Ratain MJ, Gore L, Szyldergemajn S, **Diamond JR**, Geary D, Fernandez-Teruel C, Soto-Matos A, Sharma M, Jimeno AJ. Phase I study of lurbinectedin (PM01183) administered on days (D) 1 & 8 every 3 weeks (q3wk) in patients (pts) with solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Poster Presentation, November 2014.
17. Goldenberg DM, Bahdat LT, Chuang E, Starodub A, Moroosse R, Bardia A, **Diamond JR**, Sharkey RM, Maliakal P, Hamburger SA, Ocean AJ. IMMU-132, a potential new antibody-drug conjugate (ADC) for the therapy of triple-negative breast cancer (TNBC): Preclinical and initial clinical studies. San Antonio Breast Cancer Symposium (SABCS), Poster Presentation, December 2014.
18. Bardia A, Starodub A, Moroosse RL, Mayer IA, **Diamond JR**, Chuang E, Govindan SV, Sharkey RM, Maliakal P, Wegener WA, Hamburger SA, Ocean AJ, Goldenberg DM, Vahdat LD. IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552). San Antonio Breast Cancer Symposium (SABCS), Poster Presentation, December 2014.
19. Mita M, **Diamond JR**, Richards D, Kapoun AM, Xu L, Brachmann RK, O'Shaughnessy J, Becerra C. A Phase Ib study of anti-cancer stem agent vanticumab (anti-FZD7, OMP-185R) with paclitaxel in patients with advanced HER2-negative breast cancer. San Antonio Breast Cancer Symposium (SABCS), Poster Presentation, December 2014.
20. Adams S, **Diamond J**, Hamilton E, Pohlmann P, Tolaney S, Molinero L, Zou W, Liu B, Waterkamp D, Funke R, Powderly J. Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium (SABCS), Poster Presentation, December 2015.
21. Bardia A, Isakoff S, **Diamond JR**, Mayer IA, Starodub AN, Moroosse R, Ocean AJ, Guarino MJ, Berlin JD, Messersmith WA, Thomas SS, O'Shaughnessy JA, Kalinsky K, Maurer M, Chang JC, Forero A, Traina T, Miller KD, Wilhelm F, Wegener WA, Maliakal P, Sharkey RM, Goldenberg DM, Vahdat LT. Clinical safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC. San Antonio Breast Cancer Symposium (SABCS), Poster Presentation, December 2015.
22. Ionkina AA, Eckhardt SG, Pitts TM, Kim J, Tan AC, Sartorius C, Kabos P, Tentler JJ, **Diamond JR**. Senescence as a mechanism of resistance to aurora kinase inhibition with

ENMD-2076 in p53 mutated triple-negative breast cancer (TNBC) models. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Poster Presentation, November 2015.

23. Starodub AN, Ocean AJ, Bardia A, Guarino MJ, Messersmith W, Berlin J, Picozzi VJ, Thomas SS, Masters G, Vahdat LT, Mayer I, Moroose R, **Diamond J**, Tagawa ST, Shah, MA, Wilhelm F, Wegener WA, Maliakal P, Sharkey RM, Goldenberg DM. Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Key preclinical and clinical results. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Poster Presentation, November 2015.
24. Wong KM, Gao D, McCoy H, Brock A, Powell RW, O'Bryant C, Camidge DR, Gore L, Jimeno A, **Diamond JR**, Messersmith WA, Eckhardt SG, Leong S. Predicting outcomes in patients with advanced malignancies treated on phase I clinical trials. American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2015.
25. Bardia A, Vahdat LT, Mayer IA, **Diamond JR**, Starodub AN, Moroose R, Ocean AJ, Berlin J, Messersmith W, Thomas SS, Isakoff S, Wilhelm F, Wegener WA, Maliakal P, Sharkey RM, Goldenberg DM. Therapy of refractory/relapsed triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience. American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2015.
26. Mita M, Becerra C, Richards D, Mita A, Osborne C, O'Shaughnessy J, Zhang C, Henner R, Kapoun AM, Xu L, Dupont J, Brachmann RK, Farooki A, **Diamond JR**. Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with paclitaxel (P) in patients (pts) with 1<sup>st</sup>-3<sup>rd</sup>-line metastatic HER2-negative breast cancer (BC). American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Discussion, June 2016.
27. Adams S, **Diamond J**, Hamilton E, Pohlmann P, Tolaney SM, Molinero L, He X, Waterkamp D, Funke R, Powderly J. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2016.
28. Jimeno A, Moore K, Gordon M, Chugh R, **Diamond J**, Aljumaily R, Stagg R, Kapoun A, Xu L, Dupont J, Smith D. A first-in-man phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody OMP-305B83 in patients with previously treated solid tumors. EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, Munich, Germany, November 2016.
29. **Diamond JR**, Borges VF, Kabos P, Krill-Jackson E, Burrell L, Graham R, Hoffman A, Lim B, Richards D, Salteni M, Wilks S, Patel C, Neuwirth R, Kneissl M, Zohren F. Phase Ib/II safety and efficacy of TAK-228 (MLN0128), plus exemestane (E) or fulvestrant (F) in postmenopausal women with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) metastatic breast cancer (MBC). European Society of Medical Oncology (ESMO) Annual Congress, Copenhagen, Denmark, October 2016.
30. **Diamond JR**, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson D, Capasso A, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD.

Clinical safety and efficacy of the Aurora and angiogenic kinase inhibitor ENMD-2076 in previously treated, locally advanced or metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium (SABCS), Poster Spotlight, San Antonio, TX, December 2016.

31. Bardia A, **Diamond JR**, Messersmith WA, Mayer IA, Isakoff S, Abramson V, Berlin JD, Starodub AN, O'Shaughnessy J, Kalinsky K, Moroosse R, Shah N, Dejan J, Shapiro GI, Guarino M, Ocean AJ, Wegener WA, Sharkey RM, Goldenberg DM, Vahdat LT. Sacituzumab govitecan (IMMU-132), an SN-38 anti-Trop2 antibody conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results. San Antonio Breast Cancer Symposium (SABCS), Poster Presentation, San Antonio, TX, December 2016.
32. Davis SL, Lam ET, Corr BR, O'Bryant CL, Glode A, Adler N, Pitts TM, Tentler JJ, Capasso A, Dailey K, Serkova NJ, Gustafson DL, Weekes CD, Lieu CH, Messersmith WA, Leong S, Eckhardt SG, **Diamond JR**. A phase Ib study of the combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors. EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, Poster presentation, Philadelphia, PA, November 2017.
33. Shagisultanova E, **Diamond J**, Stopeck A, Pusztai L, O'Regan R, Gradishar W, Brown-Glaberman U, Chalasani P, McSpadden T, Borakove M, Shedin T, Kabos P, Borges V. Phase IB/II open-label single arm study to evaluate safety and efficacy of tucatinib in combination with letrozole and palbociclib in subjects with hormone receptor positive and HER2 positive metastatic breast cancer (TULiP Trial). San Antonio Breast Cancer Symposium (SABCS), Poster Presentation, San Antonio, TX, December 2017.
34. Capasso A, Lang J, Pitts TM, Francoeur P, Davis SL, Lieu CH, Bagby SM, Tenter JJ, Piscopio AD, **Diamond JR**, Pelanda R, Eckhardt SG. HDAC and PD-1 inhibition in humanized triple-negative breast cancer xenografts. American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, Chicago, IL, June 2017.
35. **Diamond JR**, Eckhardt SG, Gluck WL, Gutierrez M, Peterson C, Pilar R, Benaim. Phase I study of RX-5902, a novel orally bioavailable inhibitor of phosphorylated p68, which prevents B-catenin translocation in advanced solid tumors. European Society of Medical Oncology (ESMO) Annual Congress, Poster Presentation, Madrid, Spain, September 2017.
36. **Diamond JR**, Orth J, Ionkina A, Dailey K, Pitts T, Capasso A, Davis SL, Eckhardt SG, Tentler JJ. Rational combination of mTor and Aurora kinase A inhibition in preclinical triple-negative breast cancer models. EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, Poster presentation, Philadelphia, PA, November 2017.
37. Pohlmann PR, **Diamond JR**, Hamilton E, Tolaney SM, Zhang W, Iizuka K, Foster P, Molinero L, Funke R, Adams S Atezolizumab (atezo) + nab-paclitaxel (nab-pac) in metastatic triple-negative breast cancer (mTNBC): 2-year update from a ph Ib trial. American Association for Cancer Research (AACR) Annual Meeting, Poster Presentation, 2018.
38. Serkova NJ, Singel D, Adler N, Huber K, Lee M, Brown M, Lam E, Leong S, Corr B, Purcell T, Messersmith W, **Diamond JR**. Tumor response assessment using diffusion weighted

imaging (DWI) in patients with liver metastases treated with Aurora A and TORC1/2 inhibitors. American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, Chicago, IL, June 2018.

39. Bardia A, **Diamond JR**, Vahdat LT, Tolaney SM, O'Shaughnessy J, Moroosse RL, Mayer IA, Abramson V, Juric D, Sharkey RM, Washkowitz SA, Wegener WA, Goldenberg DM, Kalinsky K. Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for endocrine-refractory hormone-receptor positive (HR+) metastatic breast cancer (mBC). American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, Chicago, IL, June 2018.
40. Tentler JJ, Kim DJ, Benaim E, Lee YB, Tan AC, Kim J, Bagby SM, Lang J, Pitts TM, Capasso A, Dailey KL, **Diamond JR**. RX-5902, a Beta-catenin modulator, enhances immunotherapy through positive alterations in the tumor immunologic environment in preclinical models of triple negative breast cancer. American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2018.
41. Atrafi F, Boix O, Rajagopalan P, Tolcher A, LoRusso P, Eder JP, Chawla S, Sankhala K, Subbiah V, **Diamond JR**, Gutierrez M, Mei J, Verweij J, Bruns I, Lolkema M. A Randomized Bayesian Phase 1 Design Combining a MPS-1 Inhibitor with Paclitaxel: a Strategy to Improve Determination of The Incremental Toxicity of a Novel Compound over a Known Backbone Therapy. American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2018.
42. Hellmann M, Naidoo J, Curigliano G, Patel S, Sahebjam S, Papadopoulos K, Jose M, Oncala F, Gordon M, Wang D, Gomez A, Song X, Li X, Marshall S, Abdullah S, **Diamond JR**. Safety and preliminary clinical activity of durvalumab in combination with monalizumab in patients with metastatic microsatellite-stable colorectal cancer. American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2018.
43. **Diamond JR**, Standifer N, Ascierto ML, Morehouse C, Canales JR, Rebelatto M, Naidoo J, Mazzearella L, Patel S, Oncala MJ, Gordo TA, Wang D, Song X, Jones DC, Ghadially H, Li X, Marshall S, Abdullah S, Jure-Kunkel M, Hellman MD. Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A). European Society of Medical Oncology (ESMO) Annual Congress, Poster Presentation, October 2018.
44. **Diamond J**, Androupoulou, Favret A, Nanda R, Gluck WL, Peterson C, Benaim E. Phase 1/2 study of RX-5902, a novel orally bioavailable inhibitor of phosphorylated p68, which prevents nuclear B-catenin translocation in patients with triple negative breast cancer. European Society of Medical Oncology (ESMO) Annual Congress, Poster Presentation, October 2018.
45. Tentler JJ, Kim DJ, Benaim E, Lee YB, Bagby SM, Lang J, Pitts TM, Capasso A, Dailey KL, **Diamond JR**. RX-5902, a beta-catenin modulator, enhances immunotherapy through positive alterations in the tumor immunologic environment in preclinical models of triple negative breast cancer. EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, Dublin, Ireland, Poster Presentation, November 2018.
46. Davis SL, **Diamond JR**. A phase Ib study of the combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid

tumors, expansion cohort data. EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, Dublin, Ireland, poster presentation, November 2018.

47. **Diamond JR**, Potter D, Salkeni M, Silverman P, Haddad T, Forget F, Awada A, Canon J, Danso M, Lortholary A, Bourgeois H, Tan-Chiu E, Patel C, Neuwirth R, Leonard J, Lim B. Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus. San Antonio Breast Cancer Symposium (SABCS), Poster Spotlight, December 2018.
48. Simmons DM, Tse TE, Dailey K, Hartman SJ, Pitts TM, Tentler JJ, **Diamond JR**. Rational combination of Wee1 and BCL-2 inhibition in preclinical models of triple-negative breast cancer. San Antonio Breast Cancer Symposium (SABCS), Poster Presentation, December 2018.
49. Hartman SJ, Bagby SM, Yacob BW, Simmons DM, Tse TE, Lieu CH, Davis SL, Leal AD, **Diamond JR**, Messersmith WA, Pitts TM. American Association of Cancer Research (AACR) Annual Meeting, Poster Presentation, April 2019.
50. Weiss JA, Nicklawsky A, Gao D, Elias A, Borges VW, Kabos P, Davis SL, Leong S, **Diamond JR**. Patients with metastatic breast cancer enrolled in phase I clinical trials: clinical outcomes and cohort trends. American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2019.
51. Jimeno A, Opyrchal M, **Diamond JR**, Fountzilas C, Corr B, Bez I, Want H, Kwan R, Ahi J, Cutler DL, Boland PM. A phase I study of the oral administration of irinotecan in combination with the potent p-glycoprotein (P-gp) inhibitor encephaloidar (NCT02250157). American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2019.
52. Cardin D, Park H, **Diamond JR**, Drilon A, VerMeulen W, He X, Hirai H, Soni N, Berlin J. Phase I study of the aurora A (AurA) inhibitor TAS-119 with paclitaxel in advanced solid tumors. American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2019.
53. Corr B, Moroney M, Sheeder J, Eckhardt SG, Sawyer B, Behbakht K, **Diamond JR**. Survival and clinical outcomes of ovarian cancer patients enrolled in phase I clinical trials. American Society of Clinical Oncology (ASCO) Annual Meeting, Poster Presentation, June 2019.
54. Maroney MR, Hill BL, Sheeder J, **Diamond J**, Avella-Howell M, Corr BR, Lefkowitz C. Integration of specialty palliative care in a phase I ovarian cancer population, Supportive Care in Oncology Symposium, Poster Presentation, 2019.
55. Maroney MR, Hill B, Sheeder J, **Diamond J**, Avella-Howell M, Corr BR, Lefkowitz C. Specialty palliative care is underutilized in a phase I ovarian cancer population. Society for Gynecologic Oncology (SGO), Annual Meeting on Women's Cancer, Poster Presentation, Toronto, Canada, March 2019.
56. Tentler JJ, D'Alessandro A, Reisz JA, Dailey KL, Capasso A, Ionkina A, Bagby SM, Pitts TM, **Diamond JR**. Combined aurora kinase a and mTORC 1/2 inhibition results in

disruption of tumor cell energetics in triple negative breast cancer. San Antonio Breast Cancer Symposium, December 2019.

57. Pitts TM, Simmons DM, Dailey K, Bagby S, Hartman SJ, Yacob BW, Gittleman B, Tentler JJ, Cittely D, Ormond R, Messersmith WA, Eckhardt SG, **Diamond JR**. Wee1 inhibition enhances the anti-tumor effects of capecitabine in preclinical models of triple negative breast cancer. San Antonio Breast Cancer Symposium (SABCS), Poster Presentation, San Antonio, TX, December 2019.
58. Chen X, Hamuro L, Coker S, Hilton J, **Diamond J**, Baldini C, Voskoboynik M, Cristea M, Edenfield W, Unsal-Kacmaz, Jackson D, Apfel A, Xu K, Zhu L, Roy A, Bello A, Fleming R, Statkevich P. Integrated pharmacokinetic (PK)/pharmacodynamic (PD) modeling leveraging PK, biomarker, and safety data to support dose and schedule selection for BMS-986158. American Association of Cancer Research (AACR) Annual Meeting, Poster Presentation, April 2020.
59. Ascierto ML, Standifer N, Si H, Patel S, Naidoo J, Banerjee S, Alonso T, Wang D, Ghadially H, Tan TH, Rodriguez J, Chen M, Kourtesis P, Lacayo J, Freeman D, Hellman M, Das M, **Diamond JR**. Clinical activity and translational endpoints observed in patients with metastatic microsatellite-stable (MSS) cancers treated with monalizumab plus durvalumab. American Association of Cancer Research (AACR) Annual Meeting, Poster Presentation, April 2020.
60. Maroney MR, Hill B, Sheeder J, **Diamond J**, Avella-Howell M, Corr BR, Lefkowitz C. Specialty palliative care is underutilized in a phase I ovarian cancer population. WAGO Annual Meeting, Poster Presentation, 2020.
61. Stoen E, Kagihara JA, Kabos P, Fisher C, **Diamond JR**. Factors associated with the uptake of adjuvant pertuzumab in patients with Stage I-III HER2-positive breast cancer: The University of Colorado Cancer Center Experience. NCCN Annual Meeting, Poster Presentation, March 2020.
62. Stoen E, Kagihara JA, Kabos P, Fisher C, **Diamond JR**. Factors associated with the use of adjuvant neratinib in stage I-III HER2-positive breast cancer. ASCO Annual Meeting, Virtual Accepted Abstract, June 2020.
63. Schreiber AR, Kabor P, Eguchi M, Meyer E, Fisher C, Bradley C, **Diamond JR**. Adjuvant chemotherapy with or without an anthracycline in older adults with node negative triple-negative breast cancer: a SEER medicare study. ASCO Annual Meeting, Virtual Accepted Abstract, June 2020.
64. Elias AD, Spoelstra N, Vidal GA, Sams S, Kabos P, **Diamond JR**, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, Borges VF, Wulfkühle J, Petricoin E, Gao D, Richer J. Phase II randomized trial of fulvestrant with or without enzalutamide in ER+/HER2- primary breast cancer (PBC). San Antonio Breast Cancer Symposium (SABCS), Poster Presentation, Virtual Meeting, December 2020.
65. Shagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner A, Stopeck A, Mayordomo J, **Diamond JR**, Kabos P, Borges VF. Interim safety and efficacy analysis of phase IB/II clinical trial of tucatinib, palbociclib and letrozole in patients with hormone receptor and HER2-positive metastatic breast cancer. San Antonio Breast Cancer

Symposium (SABCS), Poster Presentation, Virtual Meeting, December 2020.

66. Banerjee S, Oaknin A, Sanchez-Simon I, Salgado AC, Patel SP, Oza A, Das M, Kourtesis P, Ascierto ML, **Diamond JR**. Phase Ib trial of monalizumab (NKG2A inhibitor) plus durvalumab: Safety and efficacy in patients with metastatic ovarian, cervical and microsatellite-stable endometrial cancers. ESGO 2020.
67. Hamilton EP, Goel S, Arend R, Chu C, Richardson D, **Diamond JR**, Veena J, Janku F, Mathews C, JeBailey L, Kuida K, Achour H, Ruiz-Soto R, Hays J. A phase Ib/2 study of rebastanib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer. European Society of Medical Oncology (ESMO) Annual Congress, Poster Presentation, October 2020.
68. Richer JK, Spoelstra N, Winchester A, Wulfkuhle J, Sams S, Vidal G, Kabos P, **Diamond JR**, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, Borges VF, Gao D, Petricoin E, Elias AD. Correlative tumor tissue analyses of metastatic ER+/HER2- breast cancer patients treated with fulvestrant plus enzalutamide. American Association of Cancer Research (AACR) Annual Meeting, Poster Presentation, April 2021.
69. Carey LA, Loirat D, Punie K, Bardia A, Dieras V, Dalenc F, **Diamond JR**, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, O'Shaughnessy J, Loibl S, Gianni L, Piccart M, Hong Q, Olivo MS, Itri L, Cortes J. Assessment of Sacituzumab govitecan (SG) in patients (pts) with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). ASCO Annual Meeting, June 2021.
70. Moreno V, Cordoba R, **Diamond JR**, Hamdy A, Izumi R, Merz C, Boix O, Genvresse I, Nowakowski G. Safety and efficacy of VIP152, a CDK9 inhibitor, in patients with double-hit lymphoma (DLH). ASCO Annual Meeting, June 2021.
71. Kagihara JA, Corr BR, Pacheco J, Davis SL, Lieu C, Kim S, Jimeno A, Heim AM, DeMattei JA, Gordon G, Triplett TA, Eckhardt SG, Winkler J, Piscopio AD, **Diamond JR**. Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results. ASCO Annual Meeting, June 2021.
72. Hegewisch-Becker, Loirat D, Punie K, Bardia A, Dieras V, Dalenc F, **Diamond JR**, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, O'Shaughnessy J, Carey LA, Loibl S, Gianni L, Piccart M, Hong Q, Phan S, Itri LM, Cortes J. Assessment of Sacituzumab govitecan (SG) in patients (pts) with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). DGHO German Society for Haematology and Medical Oncology, 2021.
73. Lakritz S, Schreiber A, Molina E, Meyer E, **Diamond JR**. Outcomes and utilization of adjuvant chemotherapy with and without an anthracycline in node-positive triple-negative breast cancer: Analysis of SEER-Medicare data. NCCN Annual Meeting, 2021.
74. Richer JK, Spoelstra N, Winchester A, Wulfkuhle J, Sams S, Vidal G, Kabos P, **Diamond JR**, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, Borges VF, Gao D, Petricoin E, Elias AD. Response of persistent metastatic ER+/HER2- breast cancer treated with fulvestrant plus enzalutamide. SABCS, 2021.



75. Shagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner AJ, Stopeck A, Mayordomo J, **Diamond JR**, Kabos P, Borges VF. Intracranial efficacy of tucatinib, Palbociclib and letrozole combination in patients with HR+/HER2+ breast cancer and brain metastases. SABCS, 2021.
76. Carey LA, Loirat D, Punie K, Bardia A, Dieras V, Dalenc F, **Diamond JR**, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, O'Shaughnessy J, Loibl S, Gianni L, Piccart M, Hong Q, Olivo MS, Itri L, Cortes J. Assessment of Sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT. 9<sup>th</sup> National Oncology Congress, Turkey, 2022.
77. **Diamond JR**, Henry JT, Falchook GS, Olszanski AJ, Singh H, Leonard EJ, Gregory RC, Appleman VA, Gibbs JP, Harbison C, Li C, Sapiro JM, Yoneyama T, Parent A, Chung V. First-in-human study of TAK-500, a novel STING agonist immune stimulating antibody conjugate (ISAC), alone and in combination with pembrolizumab in patients with select advanced solid tumors. AACR Annual Meeting April, 2022.
78. Schreiber AS, Smoots S, Yacob B, Dominguez A, Levandowski C, **Diamond JR**, Pitts TM. Combination strategies to overcome doxorubicin-induced senescence in triple-negative breast cancer. AACR Annual Meeting April, 2022.
79. Smoots S, Schreiber AR, Yacob B, Dominguez A, Levandowski C, Pitts, TM, **Diamond JR**. Doxorubicin-induced senescence as a mechanism of resistance in TNBC cell lines. AACR Annual Meeting April, 2022.
80. **Diamond JR**, Henry JT, Falchook GS, Olszanski AJ, Singh H, Leonard EJ, Gregory RC, Appleman VA, Gibbs JP, Harbison C, Li C, Sapiro JM, Yoneyama T, Parent A, Chung V. Phase 1a/ib study design of the novel STING agonist immune stimulating antibody conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors. ASCO Annual Meeting, June 2022.
81. Elias AD, Fornier M, Vidal GA, Sams S, Spoelstra N, Kabos P, **Diamond JR**, Shagisultanova E, Crump LS, Gallagher RI, Wulfkühle J, Petricoin E, Zolman K, Biller S, Alami V, Staley A, McSpadden T, Borges V, Gao D, Richer JK. Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/HER2- breast cancer. Poster Presentation, AACR Annual Meeting, April 2023.
82. Clark EW, Hull SE, **Diamond JR**, Scalzo RL, Leach HJ. Cardiorespiratory fitness predicts diabetes risk among breast cancer survivors treated with endocrine therapy. Poster Presentation, American Society of Sports Medicine Annual Meeting, 2023.
83. Smoots S, Schreiber AR, Jackson MM, Dus ED, Bagby SM, Dominguez AT, Binns CA, **Diamond JR**, Pitts TM. Utilizing a novel HDAC inhibitor bocodopsin (OKI-179) to overcome doxorubicin resistance in triple-negative breast cancer. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston October 2023.
84. Dus E, Smoots SG, Schreiber AR, Jackson MM, Bagby SM, Dominguez AT, Binns CA, Pitts TM, **Diamond JR**. Utilizing a BCL-2 inhibitor (venetoclax) to overcome doxorubicin resistance in triple-negative breast cancer. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston October 2023.

85. Taylor MA, Zhao Q, Mareska D, Hoh M, Izrayelit Y, Litwiler K, Boys ML, Woessner R, Walker D, **Diamond JR**, Winkler JD. Discovery and characterization of OKI-219, an orally bioavailable H1047R-mutant-selective inhibitor of PI3Ka. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston October 2023.
86. Roy S, Lakritz S, Schreiber A, Molina E, Meyer E, Bradley CJ, Kondapalli L, **Diamond JR**. Major adverse cardiovascular event outcomes following adjuvant taxane+anthracycline versus taxane-based chemotherapy in older adults with triple-negative breast cancer: A SEER-Medicare study. Poster presentation, ESMO Congress Madrid, Spain, October 2023.
87. Singh H, **Diamond JR**, Henry JT, Olszanski AJ, Rasco DW, Patel SP, Gregory RC, Appleman VA, Gibbs JP, Zhang W, Wang C, Parent A, Chung V. TAK-500 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors: rationale and design of a phase 1/2 study. Poster presentation, ESMO Congress Madrid, Spain, October 2023.
88. Schreiber AR, Bagby S, Smoots S, Dominguez A, Fisher C, Lang J, Pitts T, **Diamond JR**. The effect of localized radiotherapy in combination with chemoimmunotherapy in a humanized triple-negative breast cancer model. SABCS 2023.
89. Taylor MA, Zhao Q, Mareska D, Hoh M, Izrayelit Y, Litwiler K, Boys ML, Woessner R, Walker D, Winkler JD, **Diamond JR**. OKI-219, a PI3KaH1047R-mutant-selective inhibitor demonstrates efficacy as a single agent and drives combination responses with standard of care therapies in preclinical PI3KaH1047R mutant breast cancer models. Poster Presentation, SABCS 2023.
90. Jackson MM, Smoots SG, Dus ED, Bagby SM, Dominguez ATA, Binns CA, Pitts TM, **Diamond JR**. Inhibition of BCL2 and XPO1 demonstrates synergistic effects in triple-negative breast cancer cell lines. Poster Presentation, American Association of Cancer Research (AACR) Annual Meeting, San Diego, CA, 2024.
91. Alsafar A, Kareem S, Corr BR, Lieu C, Wilky B, Davis SL, Camidge DR, Jimeno A, Nicklawsky A, McDermott JD, **Diamond JR**. Improving diversity in phase I oncology clinical trials: A single institution experience at the University of Colorado Cancer Center. ASCO Annual Meeting, Chicago, IL, 2024.
92. Shagisultanova E, Parris H, **Diamond JR**, Acharya R, Kabos P, Borges VF. Sequential therapy with HER2 tyrosine kinase inhibitors in patients with HER2-positive metastatic breast cancer. Poster Presentation, ESMO Breast, Munich, Germany, 2024.
93. Roy S, **Diamond JR**. Major adverse cardiovascular events in postmenopausal women vs pre-menopausal women with hormone receptor-positive breast cancer treated with endocrine therapy. Poster Presentation, SABCS, San Antonio, TX, 2024.
94. SERENA-1:
95. Leach HJ, Clark EW, Lyden K, Hull SE, Bolt M, **Diamond JR**, Scalzo RL. Associations between cardiorespiratory fitness, physical activity, sedentary behavior, and diabetes risk

among breast cancer survivors being treated with endocrine therapies. Moving beyond 2025. Lisbon, Portugal, 2025.

### **Original Research: Presentations at Regional Meetings**

1. Brunkow KL, Cross BR, Newton TP, Pitts TM, Eckhardt SG, Tentler JJ, **Diamond JR**. The role of p53 in mediating sensitivity to Aurora kinase inhibitors in triple-negative breast cancer, Women's Health Research Day, AMC, Poster Presentation, 2012.
2. Brunkow KL, Cross BR, Newton TP, Pitts TM, Eckhardt SG, Tentler JJ, **Diamond JR**. The role of p53 in mediating sensitivity to Aurora Kinase inhibitors in triple-negative breast cancer. Annual Retreat, CU Cancer Center, Poster Presentation, 2012.
3. Kattula S, Ionkina AA, Cross, BR, Astling D, Tentler JJ, **Diamond JR**. Preclinical analysis of paragazole (OnK101), a class I histone deacetylation inhibitor, in sensitive and resistant triple negative breast cancer cell lines, Cancer Research Summer Fellowship Poster Session, CU Cancer Center, Poster Presentation, 2013.
4. Johnson JS, Ionkina A, **Diamond JR**, Tentler JJ. Characterization of the apoptotic and senescent effects of ENMD-2076 on p53 and p73 knockdowns in triple negative breast cancer. Cancer Research Summer Fellowship Poster Session, CU Cancer Center, Poster Presentation, 2013.
5. Kattula S, Ionkina AA, Cross, BR, Astling D, Tentler JJ, **Diamond JR**. Preclinical analysis of paragazole (OnK101), a class I histone deacetylation inhibitor, in sensitive and resistant triple negative breast cancer cell lines. Women's Health Research Day, AMC, Poster Presentation, 2013.
6. Tripathi, S, Ionkina A, Pitts, TM, Tentler JJ, **Diamond JR**. Mutated p53 response to Aurora kinase inhibitors in triple negative breast cancer. Cancer Research Summer Fellowship Poster Session, CU Cancer Center, Poster Presentation, 2014.
7. Ionkina AA, Tentler JJ, Newton TP, Brunkow KL, Johnson JS, Tan AC, Pitts TM, Eckhardt SG, **Diamond JR**. The role of p53 family tumor suppressors in mediating response to the Aurora and angiogenic kinase inhibitor ENMD-2076 in triple-negative breast cancer. Annual Retreat Poster Session, CU Cancer Center, Poster Presentation, 2014 (**Top 5 Poster Winner**).
8. Ionkina, AA, Tentler JJ, Newton TP, Brunkow KL, Kabos P, Sartorius CA, Tan AC, Pitts TM, Eckhardt SG, **Diamond JR**. The role of p53 and senescence as a mechanism of resistance to Aurora kinase inhibitors in triple negative breast cancer, Department of Medicine Research Day, AMC, Poster Presentation, 2014.
9. Ionkina, AA, Tentler JJ, Newton TP, Brunkow KL, Kabos P, Sartorius CA, Tan AC, Pitts TM, Eckhardt SG, **Diamond JR**. The role of p53 and senescence as a mechanism of resistance to Aurora kinase inhibitors in triple negative breast cancer, Women's Health Research Day, AMC, Poster Presentation, 2014.